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ABBREVIATION LIST  
 
5-HT= Serotonin  
7,8 DHF= 7,8-Dihydroxyflavone 
Ab= Amiloid b 
AD= Alzheimer disease  
ADNP = Activity dependent Neuroprotective protein  
APP= Amiloid b (A4) Precursor Protein 
ARNT= Aryl hydrocarbon receptor nuclear translocator 
ASD= Autism spectrum disorder  
BBB= Blood brain barrier  
BDNF= Brain derived neurotrophic factor  
BrdU= 5-Bromo-2-deoxyuridine 
CA1= Conus Ammonis 1 
CA2= Cornus Ammonis 2 
CA3= Cornus Ammonis 3 
CAM kinase= Ca2+-calmodulin-dependent protein kinase  
cCX= Caudal neocortex  
CNS= Central nervous system  
CP= Cortical-plate 
CREB = cAMP response element-binding protein  
cSVZ= Caudal subventricuar zone  
CX= Neocortex   
DAG = 1,2-Diacylglycerol  
DG= Dentate gyrus 
DS= Down Syndrome  
DYRK1A= Dual-specificity tyrosine-phosphorylated regulated kinase 1A. 
E# =Embryonic day # 
EGCG =Epigallo-catechin-3-gallate 
ERK =Extracellular signal regulated kinase 
GM= Grey matter  
GW#= Gestational week # 
HSA21= Human chromosome 21  
HYP= Hypotalamus 
ID= Intellectual disability 
iNOS= Inducible nitric oxide synthase  
IP3= inositol-1,4,5-triphosphate  
IPSCs= Human pluripotent stem cells 
LSD= Least significance difference  
LTP= Long term potentiation  
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MAPK=Mitogen-activated protein kinase  
Mmu= Murine chromosome  
NAP= NAPVSIPQ peptide   
NFAT= Nuclear factor of activated T cells 
NT-3= Neurotrophin-3  
NT-4/5= Neurotrophin-4/5  
P= Postnatal day  
p75NTR= Receptor p75  
PI3K= PI3 kinase 
PKC = Protein kinase C  
PSD-95= Post-synaptic density protein 95 
rCX= Rostral neocortex  
ROS= Reactive oxygen species 
rSVZ= Rostral subventricular zone  
SAL= SALLRSIPA peptide 
SGZ= Subgranular zone 
SP= Sub-plate 
STR= Striatum  
SVZ= Subventricular zone 
SYN= Synaptophysin  
TH= Thalamus 
Trk= Tropomyosin-related kinase  
TrkB-FL = TrkB full length  
VZ= Ventricular zone 





Down syndrome (DS) is a genetic condition due to the triplication of human chromosome 21. DS has 
a worldwide incidence of 1:700-1000 live births. The phenotype of DS has been linked to an extra 
copy of one or more of about 300 protein coding genes. Although DS has a high genetic complexity 
and a broad phenotypic variability, intellectual disability (ID) is the unavoidable hallmark and the 
most invalidating feature of DS. ID, that lifelong affects people with DS, is mainly due to 
neurodevelopmental alterations among which neurogenesis reduction appears to play a particularly 
prominent role. Mouse models that mimic human pathologies are becoming invaluable tools, 
because they can be exploited in order to clarify the mechanisms underpinning a given pathology 
and to examine the outcome of targeted therapies. The most studied DS mouse model is the Ts65Dn 
mouse whose phenotype largely mimics the human condition. Despite intense efforts of the 
scientific community, there are currently no therapies for DS. Considering the time course of brain 
development and that the bulk of neurogenesis takes place during the embryonic period, 
therapeutic interventions aimed at correcting brain developmental defects should be started 
prenatally. Pharmacological interventions during the extremely delicate embryonic periods may 
pose some caveats. Therefore, it is important that therapies are based on molecules with a safe 
profile. 7,8-DHF is a natural flavonoid present in fruits and vegetables, is able to cross the blood 
brain barrier, and specifically binds the TrkB receptor activating its downstream signaling cascade. 
We previously found that neonatal treatment with 7,8-DHF improves cellularity and restores 
dendritic pathology in the hippocampus of the Ts65Dn model of DS. Based on these premises the 
goal of the current study was to establish whether prenatal treatment with 7,8-DHF is able to rescue 
defective neurogenesis in Ts65Dn mouse brain. To this purpose Ts65Dn pregnant females were 
treated with 7,8-DHF from embryonic day 10 until delivery. On postnatal day 2 (P2) the pups were 
injected with BrdU and killed after 2 h. In P2 mice, we evaluated the number of proliferating (BrdU+) 
cells in various forebrain neurogenic niches. Namely the rostral and caudal subventricular zone, 
dentate gyrus, rostral and caudal neocortex, striatum, thalamus and hypothalamus. We found that 
in treated Ts65Dn mice the proliferation potency was improved or even restored in most of the 
examined regions. Moreover, treatment restored cellularity in layer II of the neocortex but not in 
the hippocampus. These results show that 7,8-DHF has a positive influence on prenatal 
neurogenesis and cortical cellularity in the Ts65Dn mouse model, but, unlike neonatal treatment, it 
has moderate effects on hippocampal cellularity. Since 7,8-DHF is orally bioavailable, and in view of 
his chemical nature and no reported side effects, maternal supplementation with this molecule 
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Down syndrome (DS) OMIM 190685, a genetic condition due to the triplication of human 
chromosome 21 (HAS21), is the most common viable chromosomal abnormality in humans. DS has 
a relatively high incidence, occurring in 10-14 out 10000 live births in Europe and United States 
respectively (Dierssen, 2012). Approximately 0.45% of all human conceptions are trisomic for HAS21 
(Ruparelia, 2013). DS is characterized by different and variable phenotypic traits, but intellectual 
disability (ID) is the common hallmark of this pathology. People with DS suffer of abnormalities in 
learning, memory, and language. Their cognitive profiles may be different in terms of both the 
severity of cognitive disability and the type of cognitive function affected. In the past decades, there 
has been a substantial improvement in the life expectancy for people with DS. The survival rate for 
children under one year of age has changed from less than 50% in the 1940s to a 4.4% in the 2000s. 
Thanks to appropriate early medical care and changes in the attitude of the community now people 
with DS can live longer (around 60 years of age). Moreover, their quality of life has also notably 




The majority of DS cases (95%) are due to free trisomy 21 with a nondisjunction during meiosis (Bull, 
2011). Non disjunction occurs because of aberrant cell division during the formation of ovum or 
sperm, resulting in an extra chromosome 21 (Arumugam, 2016). Nondisjunction is more likely in 
mothers, especially in older ones, but it can occur at any maternal age (Driscoll, 2009). Another 
genetic rearrangement that can cause DS is translocation (3-4%). In this condition, an additional 
copy of chromosome 21 is partially or fully translocated to another chromosome, usually 
chromosome 14 or 15 (Arumugam, 2016; Asim, 2015; Bull, 2011). The remaining 1-2 % of individuals 
with DS show mosaicism for trisomy 21, with both normal and trisomy 21 cell lines in the same 
individual. Mosaicism results when an error occurs during mitotic cell division soon after 
conception. Persons with mosaicism may be more mildly affected than persons with complete 
trisomy 21 or translocation (Asim, 2015; Bull, 2011; Pangalos, 1994; Papavassiliou, 2013). While 
nondisjunction and mosaicism mechanism are not usually inherited, some cases of DS that result 
from translocation are associated with a genetic risk that can increase the probability of DS offspring 
(Arumugam, 2016; Bull, 2011). 
 9 
Clinical features  
 
Although DS has a high genetic complexity and a broad phenotypic variability, due to allelic 
variation, genomic imbalance, epigenetic or environmental factors (Lott, 2010) there are various 
conserved features occurring in all individuals with DS. Congenital heart disease is one of the main 
clinical features that affects people with DS (Versacci, 2018). The most frequent heart defects in DS 
are atrioventricular septal defect, atrial septal defects, ventricular septal defect, and tetralogy of 
Fallot (Asim, 2015; Versacci, 2018). It must be noted that children with DS with an associated 
congenital heart disease have poorer neurodevelopmental outcomes, probably due to a reduced 
cerebral oxygen delivery (Baburamani, 2019). Individuals with DS present a large number of 
gastrointestinal defects, such as duodenal and anal stenosis and the most frequently occurring 
Hirschprung disease (Arumugam, 2016). Children with DS are more likely than other children to have 
some hematological aberrations and disorders. These include polycythemia, macrocytosis and a 
transient myeloproliferative disorder (Roizen, 2003). Individuals with DS are also 10-20 fold more 
likely to develop leukemia, usually during early childhood (Asim, 2015). Almost all children with DS 
suffer of muscle hypotonia, usually related to skeletal muscles, that could result in ligamentous 
laxity and lead to a delay in developmental milestones (Dey, 2013; Lott, 2012).  
 
THE HUMAN CHROMOSOME 21 
 
DS is a disorder of gene expression, as it is characterized by the presence of an additional copy of 
the HAS21. HSA21 is the smallest human chromosome. The length of 21q is 33.5 Mb and that 21p 
is 5-15 Mb (Asim, 2015). Sequencing of HSA21 was completed in the year 2000 within the Human 
Genome Project (Hattori, 2000). Overall, HSA21 is among the poorest chromosomes in terms of 
functional DNA elements per Mb and this could be the reason why DS is a viable condition in the 
postnatal period (Antonarakis, 2017). However, HSA21 is among the richest chromosomes for long 
non-coding RNA encoding genes and among the poorest for microRNA encoding genes. HSA21 is 
also poor for other non-coding RNA, long interspersed nuclear elements and short interspersed 
nuclear elements (Antonarakis, 2017). Nonetheless, HSA21 encodes several classes of non-coding 
RNA and the overexpression of some of them may contribute to different phenotypes of DS. The 
overexpression of protein coding genes and non-coding RNA affects several cellular functions and 
developmental process. Among the proteins encoded by HSA21, 23 proteins are involved in signal 
transduction and 31 proteins are transcription factors that may influence the expression of other 
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genes (Antonarakis, 2017). The advances in the functional exploration of the genome have helped 
to understand the phenotypic impact of the triplication of HSA21 regarding the molecular 
mechanism of the early onset of Alzheimer disease (AD) in DS, the molecular basis of the higher 
incidence of leukemia and the identification of HSA21 regions that harbor functional elements or 
causative genetic variation for certain DS typical phenotypes (see(Antonarakis, 2017)). 
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HUMAN BRAIN DEVELOPMENT  
 
In this chapter, the ontogenesis of the human central nervous system (CNS) is briefly reviewed. 
According to the common nomenclature referring to gestation, the embryonic period starts at 
conception and lasts until the end of the seventh gestational week (GW) and the period from GW8 
to delivery is called fetal period. Nonetheless, some authors use the term embryonic for periods 
extended beyond the seventh GW.  
The development of the human CNS is a protracted and neatly orchestrated chain of specific 
ontogenetic events that begin during the third GW and extend to late adolescence and, conceivably, 
throughout the whole lifespan. Neurogenesis begins on embryonic day 42 (E42) and is completed 
by midgestation. By the end of the prenatal period major fiber pathways are complete. Postnatally, 
brain development continues, the brain size increases by four-fold during early childhood and 
reaches 90% of adult volume by the age of 6. Structural changes both in white matter (WM) and 
grey matter (GM) continue throughout childhood and adolescence, and these changes in structure 
parallel changes in functional organization that are also reflected in behavior. Both gene expression 
and environmental input are essential for normal brain development, and disruption of either can 
alter the neural outcomes (de Graaf-Peters, 2006; Stiles, 2010).  
 
The prenatal brain  
 
Two weeks after conception the embryo is an oval-shaped two-layered structure, with the upper 
layer containing epiblast cells that will differentiate into the three primary stem cells lines and the 
lower layer containing hypoblast cells that will form extraembryonic tissues. During gastrulation, 
GW3, neural stem cells start to differentiate from the stem cells lines as a result of complex 
molecular signaling, such as gene expression as well as environmental cues. Neural progenitors lay 
in the region of the embryo called neural plate. The subsequent folding of the neural plate will form 
a hollow tube, called neural tube, which is the first step in the establishment of the CNS. The neural 
progenitors located in the most rostral part of the neural tube will give rise to the brain, while the 
more caudal cells will give rise to the hindbrain and spinal cord (Stiles, 2010). As the brain grows 
and becomes more complex, the shape of the hollow cavity changes, forming the ventricular 
systems of the brain. The neural progenitors are located in the region that will become the ventricles 
of the brain, the ventricular zone (VZ). By the end of GW8 the shape of the nervous system 
undergoes drastic changes. The anterior part of the neural tube expands, forming three brain 
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vesicles. The most anterior one is called the prosencephalon, from which the telencephalon and the 
diencephalon will be arranged. The middle vesicle is the mesencephalon, precursor of midbrain 
structures, and the most posterior is the rhombencephalon, which will be further subdivided into 
the metencephalon and myelencephalon (Stiles, 2010).  
 
Fig. 1. Changes in the morphology of the embryo. A. The emergence of the neural ridges on E19. B. Folding of the neural 
ridges and neural tube formation. C, D. Closure of the neural tube. E. Following the closure of the neural tube, the embryo 
begins to expand particularly in anterior regions. The primary vesicles are evident by E28. These include the 
Prosencephalon, Mesencephalon, and Rhombencephalon. F. By E49 the secondary vesicles emerge. The Prosencephalon 
differentiates into the Telencephalon and Diencephalon, and the Rhombencephalon into the Metencephalon and 
Myelencephalon. E=embryonic day. From (Stiles & Jernigan, 2010).  
 
From GW9 the fetal period begins and the gross morphology oh the brain undergoes dramatic 
changes. The brain from a lissencephalic structure gradually develops the characteristic pattern of 
sulcal and gyral folding. The first evidence of the future cortex is the formation of the preplate, a 
transient structure that contains various predecessor cells migrating to their final destination. The 
preplate is located between the proliferative zone and the pial surface, which is the outer surface 
of the developing brain. When migrating neuroblasts reach the preplate, their migration stops and 
the preplate is split into two layers: the future cortical layer I and the subplate. The subplate is a 
temporary target of afferent fibers originating from the thalamus, brainstem nuclei, and 
hemispheres and also acts as a reservoir for maturing neurons and transient synapses. It regresses 
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after 31 weeks, coinciding with the expansion of gyration, and completely disappears after birth 
(Girard, 2016). 
At GW7, the germinal matrix can be divided into VZ, and an underlying subventricular zone (SVZ). 
Approximately from E25 to E42 the population of neural stem cells, located in the proliferative 
niches, divides in a symmetrical mode and from one neural progenitor the division produces two 
identical neural progenitor cells. From E42, the cell division gradually shifts to an asymmetrical 
mode and from one neural progenitor the division produces one neural progenitor and one neuron. 
The new progenitor remains in the proliferative niche and continues to divide, while the postmitotic 
neuron leaves the proliferative zone and migrates to the neocortex. In most areas of the human 
brain neurogenesis is completed by approximately E108 (de Graaf-Peters, 2006; Jessell, 2000; Stiles, 
2010). Neurons arise in the VZ and SVZ and migrate radially to their definitive destination before or 
during differentiation. Early in development the distance neurons must traverse is small, thus they 
migrate using somal translocation; the neuron extends a basal process out of the VZ to the pial 
surface, the nucleus of the cell moves up trough cytoplasm of the basal process and reaches the pial 
surface. As development proceeds the distance becomes larger and neuron migration requires a 
special cell population, the radial glial cells. The radial glia cell extend a process from the VZ to the 
pial surface and the migrating neurons use the radial glia process as a scaffold to migrate into the 
developing cortical plate (Bystron, 2008; Jessell, 2000; Stiles, 2010). 
During early brain development neural progenitor cells are able to produce any neuron type, but as 
development proceeds following intrinsic cell signaling, they became more restricted in the types 
of neurons they can produce. The selection of the neural fate depends on diverse cellular signaling 
and complex molecular interactions between neurons and glia cells regulate the cellular migration. 
Moreover, a relationship exists between the time a neuron is born and differentiates and its final 
destination. For example, the migration of the cells that are going to shape the cerebral cortex 
occurs in an inside-out order with the oldest neurons travelling to the deepest cortical layer, and 
the youngest neurons locating in the more superficial layers (de Graaf-Peters, 2006; Girard, 2016).  
Once neurons have reached their target region they arborize and branch in order to establish 
appropriate connections with other neurons and become part of processing networks. Once the 
axon has reached its target, synapses are formed with the target cell (Jessell; Stiles, 2010). Dendritic 
development starts early during fetal life, accelerates from the third trimester, and remains active 
till the end of the first postnatal year. Several growth factors such as the brain-derived neurotropic 
factor (BDNF), nerve growth factor (NGF) and glia-derived growth factor influence the migration and 
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maturation of neurons that reaches the highest levels during the prenatal period when neurons first 
establish synaptic contacts. Finally, immediately before birth approximately 50% of all neurons are 
eliminated with the goal to increase efficiency of synaptic transmission and for the establishment 
of functional networks in the developing brain (Andersen, 2003; de Graaf-Peters, 2006; Girard, 
2016; Stiles, 2010). In the human forebrain, neocortical neurons are generated during a restricted 
period that begins at approximately GW6 and is largely completed by GW18. By GW24, the size of 
the VZ and SVZ is considerably reduced and there is a marked decrease in proliferative activity. 
While, in the dentate gyrus (DG) and cerebellum the period of neurogenesis is prolonged in 
comparison with the other brain regions, neurogenesis begins at approximately GW 12 and is almost 
accomplished within the first postnatal year (Stagni, 2018a).  
Neurons are thought as the fundamental unit of the CNS, but they are dependent on, interact with 
and are surrounded by glia cells. Similarly to neurogenesis, gliogenesis within the CNS occurs during 
embryonic development. The peak of gliogenesis takes place between GW20 and GW40, after the 
peak of neurogenesis has passed. Macroglia cells arise from neural progenitors in the VZ and SVZ, 
as neurons themselves, and then migrate to their final destination. The most prominent macroglial 
populations are oligodendrocytes, responsible for the formation of myelin, and astrocytes, which 
play a role in the regulation of the composition of extracellular environment, clearance of excess of 
neurotransmitters and modulation of formation and efficiency of synaptic connections (de Graaf-
Peters, 2006). 
Neurotransmitters and neuromodulatory substances play a fundamental role in the development 
on the nervous system, driving neuronal migration and differentiation and shaping synaptic 
circuitries. The major neurotransmitters are present from early prenatal stages onwards and their 
relative expression and concentration can change throughout pregnancy and postnatally. Nicotine 
acetylcholine receptors can be detected in different brain areas from GW6. After GW24 cholinergic 
innervation obtains a pattern of topographical relationship which can be compared to that of the 
human adult brain. The catecholaminergic system also emerges during early development, 
dopaminergic and noradrenergic cells can be found in several brain areas at GW8 and between 
GW22-26 dopaminergic and noradrenergic innervation becomes visible throughout the cerebral 
cortex. GABAergic cells originate in the ganglionic eminence. During early development the GABA 
inhibitory neurotransmitter acts as an excitatory transmitter; the switch from excitatory to 
inhibitory occurs during the last trimester of gestation. Glutamate receptors are found in the fetal 
cortex starting from GW10, with two different period of transient increased expression. The 
 15 
serotoninergic innervation occurs very early and does not change after the fetal age (de Graaf-
Peters, 2006; Girard, 2016).  
 
The postnatal brain  
 
As mentioned above, at advanced stages of embryogenesis the VZ decreases in size and is gradually 
replaced by the SVZ, that plays pivotal role in corticogenesis during the early postnatal period. 
However, after early infancy, the human SVZ shows little to no neurogenesis. The few existing 
neuroblasts found in the adult SVZ migrate to the olfactory bulbs at lower extent. Neurogenesis in 
the DG continues, at a slow rate, throughout the whole life. Granule neurons are generated in the 
subgranular layer from which they migrate to the nearby granular layer (Conover, 2017). Unlike 
neurogenesis, proliferation and migration of glial precursors continues for an extended period after 
birth and the process of differentiation and maturation of astrocytes and oligodendrocytes 
continues throughout childhood. The myelination process occurs in a linear way throughout 
childhood and adolescence. Glia cells contribute to the maintenance of axonal integrity and 
neuronal survival through the release of trophic factor. The length of axons and dendrites increases 
five to ten times during the first six postnatal months and dendritic growth of cortical neurons 
continues till the age of 5 years. In parallel to the axonal and dendritic development the number of 
synaptic connections increases. In the developing brain the number of connections is exaggerate 
both at the macroscopic level within the major brain areas that form transient connections through 
the brain, and at the microscopic level, with the number of synapses during the early postnatal 
period that doubles that observed in the adult brain (Foulkes, 2018; Girard, 2016; Stiles, 2010). 
During the preadolescence period, a second wave of neuronal rearrangement occurs with the 
pruning of synapses, receptors, and overproduced glia cells. Many factors concur to the retention 
and eliminations of connections, such as competition for resources and afferent input. The process 
of synapse production and elimination is different across brain regions and parallels the functional 
development of each region (Andersen, 2003; Khundrakpam, 2016; Stiles, 2010). 
During adolescence, the human brain undergoes significant structural change also in terms of GM 
volume, surface area and cortical thickness, as well as WM volume and microstructure. The total 
volume of the WM increases during childhood and adolescence, probably reflecting increased 
myelination, leading to better connectivity as well as enhanced signal integration. In contrast, the 
volume of the cortical GM increases during early childhood but subsequently declines throughout 
adolescence, reflecting the initial synapse overproduction and the subsequent pruning. It is 
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interesting to note that the age of peak of GM density is associated with specific functional and 
cognitive development. It has been observed earliest in primary sensorimotor areas and latest in 
higher-order association areas (Girard, 2016; Khundrakpam, 2016). 
As a physiological process, the human brain shows a progressive decline during aging. The brain 
shrinks during advanced age, with reductions in both GM and WM and an associated enlargement 
of the cerebral ventricles. GM volume begins to decrease after adolescence. The age-related 
reduction in the GM is most prominent in the temporal and frontal lobes (Mattson, 2018). The brain 
atrophy and the decline in GM volume in older adults is explained not only by neuronal death but 
also by a decrease in cells size, decreased number of connections between neurons, reduced 
complexity of dendrite arborization and length, and decreased dendritic spines. During advanced 
life stages, a reduction in WM volume also emerges. A 16% to 20% decrease in the volume of WM 
has been demonstrated in subjects older than 70 years in comparison with younger subjects 
(Harada, 2013). 
 
Fig. 2. Timing of neurobiological processes in the telencephalon during human ontogeny. W= week, M= postanal 
months, Y= years, P= onset of puberty, A= onset of adulthood. The broken line means that the process is active, a bold 
line indicate that the process is very active. In the lower part, the development of various neurotransmitter system is 
represented, thin broken line means that the transmitter is present, a continuous bold line represents an overexpression 
of the transmitter. The increasing dot density in the catecholaminergic systems denote the gradual increase in 
dopaminergic activity. The bold broken line in the GABAergic systems reflects that GABA in early life exerts an excitatory 
function and later switches to its inhibitory function. From (de Graaf-Peters, 2006). 
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BRAIN DEVELOPMENT IN DOWN SYNDROME 
 
The prenatal brain  
 
DS is characterized by brain hypotrophy and intellectual disability starting from early life stages. 
Several studies have focused on the neuroanatomical correlates of cognitive impairment in DS. This 
section summarizes information on neuroanatomical defects and neurogenesis alterations in the 
brain of individuals with DS, starting from early developmental stages.  
Individuals with DS have an overall reduced brain volume and numerous brain regions appear to be 
smaller in comparison with controls (Stagni, 2018a). A pioneering study by Schmidt-Sidor in fetuses 
at GW15-22 found no gross differences in brain shape, weight and fronto-occipital length and no 
differences in the volume of the cerebellum and hippocampus (Schmidt-Sidor, 1990). This is in 
contrast with the hypotrophy of the DS brain reported in other following studies regarding the DS 
fetal brain. The absence of differences in Schmidt-Sidor’s study may be attributable to the fact that 
fetuses were not stratified by age, which, may obscure differences between DS and non-DS fetuses. 
In fact, the evaluation of the brain of fetuses with DS during restricted time windows revealed a 
reduction in brain size starting from 4-5 month-old-fetuses (Guihard-Costa, 2006). A size reduction 
has been revealed in various brain structures such as the subiculum, hippocampus, inferior temporal 
region, and cerebellum of fetuses with DS at GW17-22 (Guidi , 2008; Guidi, 2011; Guidi, 2018; Stagni, 
2018; Stagni, 2019). Moreover, in addition to weight and volume alterations, the fetal DS brain is 
brachycephalic due to a reduction in the length of the frontal lobe and an increase in the 
transparietal length (Guihard-Costa, 2006). It has been suggested that the neurodevelopmental 
abnormalities of DS arise from a decreased production of neurons during critical phases of brain 
development. Indeed, several studies reported a reduced number of neurons in several brain 
regions of fetuses and children with DS (Guidi , 2008; Stagni, 2018b; Stagni, 2018a). It has been 
proposed that aberrant copies of a single chromosome could alter the cell cycle and, thus, the 
proliferation rate during development. Accordingly, it has been hypothesized that in DS, an extra 
copy of chromosome 21 may affect the cell cycle of neuronal precursor cells during neurogenesis. 
In fact, in fetuses with DS (GW17-23) the number of proliferating cells is reduced in the DG of the 
hippocampus, hippocampus proper, parahippocampal gyrus, the germinal matrix of the inferior 
horn of the lateral ventricle, external granular layer of the cerebellum, in a region of the fifth 
cerebellar lobe that is the remnant of the cerebellar ventricular zone (Contestabile, 2007; Guidi, 
2011), and in the frontal cortex (GW 18) (Lu, 2012). The analysis of the cell cycle of trisomic neural 
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progenitors has demonstrated an elongation of the G2 phase, which possibly accounts for the 
reduced proliferation rate found during neurogenesis in the DS brain (Contestabile, 2007; Guidi, 
2008). In addition to having a reduced number of neurons, the cortex of fetuses with DS exhibits a 
delay in the emergence of lamination and has a disorganized appearance (Stagni, 2018a). An 
additional confirmation of defective neurogenesis in DS derives from in vitro studies showing that 
neuronal precursors isolated from DS fetal brains and cultured as neurospheres give rise to reduced 
numbers of neurons when differentiated (Lu, 2012). The reduced proliferation potency of the 
trisomic brain is worsened by a reduction in the acquisition of a neuronal phenotype accompanied 
by a relative increase in the acquisition of an astrocytic phenotype (Guidi, 2008). In addition to 
neurogenesis impairment, an increase in apoptotic cell death had been found in the DG and SVZ of 
fetuses with DS, suggesting that alterations of both neurogenesis and programmed cell death may 
concur to the hypocellularity found in DS brains (Guidi, 2008). However, the role of apoptosis 
remains unclear and the results from different studies are still contradictory. Upregulation of some 
pro apoptotic factors, downregulation of anti-apoptotic factors and apoptosis-associated proteins 
have been found in different cortical and cerebellar regions of DS fetuses (Helguera, 2005; Seidl, 
2001). Although some studies reported an enhancement of apoptosis, the number of cells 
undergoing programmed cell death is very low, suggesting that this process does not have a 
prominent role in reducing the final neuron number in the DS brain (see (Stagni, 2018a)). 
Harmonious development of the CNS during prenatal development does not only require an 
accurate course of genetic schedules but also depends on appropriate signaling processes. 
Neurotransmitters and neuromodulatory substances have established roles in the maturation of the 
CNS. Neurochemical alterations of several neurotransmitter systems have been found in the fetal 
DS brain. In particular, the brain of DS fetuses shows reduced levels of i) GABA, that is the main 
responsible for the excitatory neurotransmission in the developing brain; ii) taurine, that acts as a 
neurotropic factor during brain development; iii) dopamine, that is fundamental for the 
establishment of synaptic contacts; and iv) serotonin (5-HT), that is crucial for neuronal 
proliferation, differentiation, migration and synaptogenesis (Whittle, 2007).  
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Fig. 3. Brain hypotrophy in DS fetuses. A-C. Examples of brain (scale bar 1 cm), hippocampus (scale bar 1mm) and 
cerebellum (scale bar 2mm) of diploid and DS fetuses (GW17-21). DS= Down syndrome. From (Guidi, 2008; Guidi, 2011; 
Stagni, 2018). 
 
The postnatal brain  
 
The shape alterations present during fetal life stages are retained in the brain of infants and children 
with DS. Morphometric studies in children with DS show architectonic abnormalities and reduced 
cellularity both in cortical and extracortical regions (Stagni, 2018a). The brains of children with DS 
have a reduced volume in comparison to typical children, both of the GM and WM. With the 
exception of the occipital lobes, all brain lobes have a reduced size, and volume reduction is also 
present in the hippocampus and cerebellum (see (Stagni, 2018a)). There is evidence for a reduced 
number of neurons in the cerebellar granule cell layer and in the cortex of children with DS (Baxter, 
2000; Buxhoeveden, 2002). Moreover, the astrocytic hypertrophy and the increase in astrocyte 
number present in the DS brain during fetal life stages is maintained in adulthood (see (Stagni, 
2018a)). 
The sprouting of dendrites in the first postnatal period of the typical brain development contrasts 
with the progressive reduction that affects children with DS. Infants with DS begin their lives with 
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normal or even increased dendritic branching and abnormalities in cortical dendrites start to appear 
during the first year of age. The dendritic arborization and the number of dendritic spines poorly 
increase in children with DS and the dendritic atrophy seen in childhood progresses during 
adulthood, with marked reduction of dendritic branching, length, and spine density in elderly adults 
(Becker, 1986; Marin-Padilla, 1976; Takashima, 1981; Takashima, 1994). Given the role of dendrites 
and dendritic spines as essential structures for brain connectivity and plasticity, it is straightforward 
to postulate that alterations in these neuronal microcompartments may affect neuronal network 
activity.  
During aging, brain atrophy superimposes on the pre-existing developmental alterations that 
characterize the brain of people with DS. MRI studies have reported atrophy of the medial temporal 
lobe, including hippocampus, amygdala, and of neocortical regions such as the corpus callosum and 
the parietal, frontal, and occipital cortices in aged non-demented DS patients, suggesting prodromal 
stages of AD-like pathology (Teipel, 2006). Decreased levels of excitatory neurotransmitters, 
monoamines, histamine, and 5-HT, as well as reduced activity of the histamine synthetase enzyme 
have been detected in various regions of the adult DS brain, suggesting profound alterations of 
neuronal network activity. Moreover, deficits in the cholinergic system, similar to those occurring 
in AD, have been demonstrated in the brain of adult with DS. Degeneration of basal forebrain 
cholinergic neurons and a decreased activity of choline acetyltransferase, that start during late 
adolescence and adulthood, have been observed in both DS and AD (Contestabile, 2008; Whittle, 
2007).  
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NEUROLOGICAL DEFECTS IN DOWN SYNDROME   
 
The neuroanatomical alterations that characterize the DS brain from the first embryonic stages of 
development to old age undoubtedly play a key role on the several neurological problems that affect 
people with DS. The trisomy of chromosome 21 is the most common genetic cause of intellectual 
disability and account for 15% of the population with ID (Ruparelia, 2013). DS people show altered 
cognitive and behavioral phenotypes with a delayed and incomplete acquisition of motor, linguistic 
and visuospatial abilities, impairments in learning and memory and neurobehavioral disorders 
(Bartesaghi, 2011). However, there is a great interindividual variability both in the nature and 
intensity of cognitive impairment (Rueda, 2012). 
Intellectual capacity. The intelligence quotient (IQ) in people with DS lays usually in the moderately 
to severely retarded range (IQ=25-55) and Mental Age is rarely above of 8 years. However, few 
individuals with DS have been reported to have IQ in the normal range. It must be also remarked 
that IQ in adults with DS may be also influenced by the increased risk of early onset dementia (Vicari, 
2006). It is estimated that among children affected by DS, 10% have profound intellectual disability, 
70% severe, and 20% mild or none. Infancy is characterized by a delay in cognitive development and 
while there is an improvement in cognitive skills during infancy, the IQ plateaus or even decreases 
starting from adolescence (Dierssen, 2012; Lott, 2010). The behavioral phenotype associated with 
DS emerges in infancy and accumulates in early childhood, with impairments of speech, language, 
motor skills, cognition, and adaptive behavior.  
Learning and memory impairment. Learning and memory problems in children with DS emerge in 
late infancy and become more noticeably during adolescence (Lott, 2010), when the acquisition of 
skills and the cognitive growth become slower (Grieco, 2015). Learning deficits involve both short-
term and long-term memory domains. In particular, DS children perform worse than normal 
children in task requiring explicit type of memory, like verbal short-term memory, while they show 
normal learning ability in tasks that require implicit memory, indicating a functional dissociation 
between implicit and explicit memory. Moreover, they show difficulties in both long- and short-
term spatial memory, mainly at the levels of encoding and retrieval, but they have normal 
performance in simple tasks like associative learning, (Godfrey, 2018; Grieco, 2015; Silverman, 
2007). Starting from adolescence, deficits in verbal short term memory continue and specific 
working memory deficits became evident (Godfrey, 2018; Grieco, 2015). Both hippocampal- and 
prefrontal-related functions appear defective in individuals with DS. Furthermore, children with DS 
show impairments in distinct aspects of attention, and selective attention deficits persist through 
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adulthood. Deficit in attention and high processing demand together with impaired language 
comprehension and weakness in verbal information processing can contribute to adversely impact 
learning and memory performances in individual with DS (Grieco, 2015). All these defects are 
probably due to brain structural abnormalities, in particular at the level of the medial temporal lobe 
and prefrontal cortex (Lott, 2010).  
Visuo-spatial abilities. Visuo-spatial short-term memory domain in individual with DS is usually 
consistent with their mental age. However, in recognition tasks, when memory demand increase or 
when visual and spatial demands are combined, the performance of DS children is impaired 
compared with mental age-matched controls (Vicari, 2006; Visu-Petra, 2007).  
Linguistic abilities. Despite rare exceptions people with DS usually exhibit very poor linguistic 
capacities when compared with typical developing peers of the same mental age. Infants with DS 
show many of the normal features of paralanguage behavior, but they show slowest rates of 
development in grammatical morphology, a longer period of phonological errors and poorer 
intelligibility, although language comprehension is more advanced than syntax (Vicari, 2006).  
Seizures. It is estimated that 5-13% of children with DS have seizures. Seizures occurrence in DS is 
bimodal, 40% of people develop seizure before 1 year of age, and another 40% develop seizure after 
the third decade of life (Lott, 2012; Roizen, 2003). Seizure, if uncontrolled, can impair cognitive 
function. Infantile spasm and myoclonic seizure in children have been linked to structural brain 
abnormalities, such as fewer inhibitory neurons, abnormal cortical lamination, and impaired 
dendritic morphology (Lott, 2010). Seizures in adult with DS are often associated with dementia and 
early onset of Alzheimer disease (Lott, 2010). 
Autism spectrum disorder. In children with DS, ID together with the expression of other social and 
behavioral differences leads to a profile that carries increased risk for language impairment and 
other comorbid developmental disorders such as autism spectrum disorder (ASD). Current 
estimates suggest that approximately 7–19% of individuals with DS have comorbid ASD. Despite the 
relatively high prevalence of ASD in DS, the nature of this comorbidity is still poorly understood. This 
has led to discrepant findings regarding the prevalence rate and how to identify ASD in individuals 
with DS who carry their own phenotypic profile with potentially overlapping features of ASD (see 
(Channell, 2019)). 
Dementia and Alzheimer’s disease. Dementia resembling Alzheimer disease (AD) is among the most 
significant age-associated concerns in DS. By the age of 40 the brain of individuals with DS presents 
the characteristic signs of AD neuropathology, including senile plaques and neurofibrillary tangles, 
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and by the age of 65 the majority of people with DS are likely to develop dementia (Godfrey, 2018; 
Lott, 2012; Ruparelia, 2013). In trisomy 21 there is an overexpression of the gene for APP (Amiloid 
beta precursor protein) from which the amyloid beta protein derives and intraneuronal 
accumulation of amyloid beta appears to trigger the neurodegeneration cascade. Moreover, 
overexpression of DYRK1A (dual-specificity tyrosine-phosphorylated regulated kinase 1A), located 
on chromosome 21, through the hyperphosphorylation of tau that is responsible for the formation 
of neurofibrillary tangles, may also contribute to the early onset of neurofibrillary degeneration 
(Lott, 2012). 
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MOUSE BRAIN DEVELOPMENT 
 
Mouse models that mimic human pathologies are invaluable tools, that are essential in order to 
identify the mechanisms underpinning a given pathology and to examine the outcome of targeted 
therapies. In this chapter, the events that take place during brain development in mice are briefly 
described, with a particular focus on prenatal neurogenesis.  
 
The prenatal brain  
 
In mammals the neural tube formation is a highly dynamic process that takes place early during 
embryogenesis, between GW3 and 4 in humans, and between E8.5 and E10.0 in mice (Massarwa, 
2013). At E9.5, with the appearance of the cerebral vesicles from the dorsal surface of the rostral 
neurotube, the development of murine neocortex begins. Initially, the primordial neocortex is 
comprised of an apparently homogeneous pool of neural stem cells. Starting from E10.5 the first 
post mitotic neurons of the cortex, the Cajal-Retzius cells, arise. The bulk of neurogenesis in mice 
takes place at E11, when an active neuronal generation and migration of several neuronal 
populations occur in many brain regions (Sansom, 2009). 
The VZ and SVZ are the two germinal regions of the embryonic mammalian brain. The progenitors 
of the neurons and glia forming the telencephalon emerge from the embryonic VZ/SVZ of the lateral 
ventricle. The VZ is the most active neurogenic niche during the early phase of brain development. 
Soon after the emergence of the first neurons from the VZ, a second proliferative population is 
discernable at the edges of the VZ, formed by the SVZ cells. The SVZ cell population expands rapidly 
and becomes the major brain neurogenic niche during the latter third of the prenatal development 
and peaks in size during early postnatal development (Brazel, 2003). Four distinct divisions of the 
SVZ can be distinguished in the forebrain during fetal development, the medial ganglionic eminence 
(MGE), the lateral ganglionic eminence (LGE), the caudal ganglionic eminence (CGE) and the fetal 
neocortical SVZ (SVZn). Each region is constituted by cell progenitors that generate diverse types of 
neurons and glia, which will populate different regions of the brain (Brazel, 2003) (Fig. 4). Both the 
MGE and LGE contribute to the development of several brain structures, including the neocortex, 
striatum, thalamus, septum, and olfactory bulb. The majority of the MGE progeny contributes to 
the neocortex, although some evidence suggests that the LGE may play a role in the neocortex 
formation too. It has been established that neocortical interneurons, Cajal-Retzius cells and 
GABAergic interneurons arise from the MGE progeny. Both the MGE and LGE contribute to the 
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formation of the striatum, during embryogenesis, although the major contribute is played by the 
LGE. The MGE have a key role also in the hippocampal neurogenesis, in particular the MGE is a 
primary source for hippocampal GABAergic interneurons. The CGE cells migrate to the hippocampus 
and cortex but also to the nucleus accumbens, bed nucleus of the stria terminalis, hippocampus, 
select nuclei of the amygdala, posterior striatum, and posterior globus pallidus (Brazel, 2003; Nery, 
2002).  
The cells that originate from ganglionic eminences contribute also to the gliogenesis of the 
developing brain. The onset of gliogenesis in the cortex commences after the bulk of neurogenesis 
has taken place, the appearance of the first differentiated astrocytes occurring around E18. 
Gliogenesis persists long after neurogenesis has ceased and continues during the postnatal period. 
The number of mature astrocytes peaks in the neonatal period, and differentiated oligodendrocyte 
are first seen postnatally (Miller, 2007). The cells of the VZ are direct descendants of the neural 
plate; they differentiate prenatally into radial glia cells, neurons, and astrocytes. The radial glia 
spans the width of the developing brain and with their projection serve as a guide for migrating 
neurons. Immature neurons settle into specific cortical laminae dictated by their birth date and, 
with the exceptions of the Cajal-Retzius cells, corticogenesis follows an inside-outside pattern, 
earlier born neurons settle into deeper laminae and later born neurons colonize more superficial 
layers (Brazel, 2003; Sansom, 2009). It has been suggested that VZ cells preferentially produce deep 
layer neurons of the neocortex, whereas SVZ cells are destined to produce neurons of the more 
superficial neocortical layers (Brazel, 2003; Sansom, 2009). 
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Fig. 4. Contribution of the ventricular zone, subventricular zone, medial ganglionic eminence, lateral ganglionic 
eminence, and caudal ganglionic eminence to early brain development. A. Coronal view of the rodent forebrain 
germinal zones at E12.5. B. The MGE and LGE are prominent structures in E15.5 brain. C. Directional movements of MGE 
and LGE cells as they migrate. D. Sagittal view of the rodent brain at E15.5 shows directional movements from the MGE, 
LGE and CGE. CGE=caudal ganglionic eminence; E=embryonic day; LGE=lateral ganglionic eminence; MGE=mediall 
ganglionic eminence; SVZ=subventricular zone; VZ=ventricular zone. From (Brazel, 2003). 
 
The postnatal brain 
  
While the bulk of neurogenesis in the mouse brain is a prenatal event, there are two exceptions for 
this rule, the hippocampal DG, and the cerebellum. The cerebellum appears on E10-12 as an 
evaginated thickening in the anterior part of the roof of the fourth ventricle (Miale, 1961). 
Cerebellar neurogenesis begins approximately at E15 and continues in the first two postnatal weeks. 
Purkinje cells and Golgi cells are generated prenatally, around E11-13 and E12-15, respectively 
(Fujita, 1967; Miale, 1961). Cerebellar granule cells arise at late embryonic stage and their 
neurogenesis continues until P15. Cells of molecular layer arise mainly during the first postnatal 
week (Fujita, 1967; Marzban, 2015; Miale, 1961). By P16 all cerebellar cells types are organized in 
layers, and the morphology and molecular domains are correlated with the localization of specific 
cerebellar circuits (Sillitoe, 2007). In the DG of the hippocampus neurogenesis begins during the 
embryonic period, at E10, but it is not accomplished at birth, it continues until puberty and, at slow 
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rate, is maintained for the whole life. Neurons forming the DG derive from the hippocampal 
neuroepitelium which will give rise to the postnatal subgranular zone (SGZ). The SGZ becomes 
thinner as the DG grows but the granule cell precursors that remain in the SGZ retain their 
neurogenic abilities in the adult brain. The first granule cells that form the DG are generated in the 
hippocampal neuroepitelium and migrate to the hilus. The new generated granule cells arise from 
the germinal zone of the DG and accumulate under the oldest cells. Therefore the DG is shaped in 
an outside-inside fashion, with the oldest granule cells being the most superficial cells and the 
youngest being the deeper cells (Altman 1990.; Altman, 1990b). 
While neurogenesis, with the exceptions of the DG and cerebellum, is a prenatal event, neuron 
migration and maturation, as well as differentiation and maturation of astrocytes and 
oligodendrocytes, occur perinatally (Brazel, 2003; Miller, 2007; Stagni, 2015). Neurons migrate to 
the GM, WM and striatum using radial glia process as guide to the migration but also nascent WM 
tracts. Cells continue to divide as they migrate, and their differentiation is regulated by local signals 
they receive once they cease to migrate (Brazel, 2003). In the postnatal brain the SVZ has replaced 
the VZ as main source of brain cells and can be divided in a rostral and a dorsolateral part. Cells 
located in the anterior part of the SVZ are the major source of the rostral migratory stream (RSM) 
cells. They migrate to the olfactory bulb to become perigromerular and granule cells. In the anterior 
part of the SVZ, glial precursors also arise that will colonize the anterior part of the neocortex (Pino 
, 2017; Marshall, 2003). During the perinatal period, the dorsolateral part of the SVZ gives rise to 
neocortical and striatal glial cells and acts as a major source of GM and WM microglia. Cells born in 
the dorsolateral part of the SVZ in the perinatal period preferentially colonize the GM, while at the 
beginning of adolescence they increase their preference towards the WM. Indeed, in rats aged 2 
days (P2), 80% of the cells belonging to the dorsolateral SVZ labeled with retrovirus migrate to the 
neocortex, 10% migrate to the WM, and the remaining cells migrate to either the striatum or to the 
border regions between WM and neocortex or striatum. In P14 rats, 80% of the labeled cells 
colonize the WM and the remaining cells migrate to the striatum or to the border region (Brazel, 
2003; Levison, 1993). 
After P7, the rodent brain starts to acquire the features of a more mature brain. Axons and dendrites 
arborize, and dendritic spines develop. Synapses mature over the first three postnatal weeks 
following a different time schedule in diverse brain regions. Oligodendrocytes differentiate and 
myelination occurs. A wave of functional rearrangement removes, by programmed apoptosis, a 
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large number of neurons and neuronal processes produced during early brain development 
(Brumwell, 2006; Rice, 2000).  
 
Fig. 5. Schematic representation of the timeline of brain development. Timeline of neurogenesis, migration and 
maturation in the cortex, dentate gyrus and cerebellum of mouse (A) and humans (B) during brain development. Dotted 
arrows indicate a reduction in the rate of neurogenesisis. The double-headed red arrows delineate the period of 
maximum neurogenesis. CB=cerebellum; Cx=neocortex; DG=dentate gyrus; E=embryonic; F=fetal; M=month; 
P=postnatal; W=week.  
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MOUSE MODELS FOR THE STUDY OF DS 
 
Trisomy 21 is a complex genetic perturbation which makes it difficult to create models of this 
pathology. To date, various DS mouse models that replicate some aspects of the human condition 
have been created. The long arm of HSA21 contains 33.7 Mb and approximately includes ~160 
encoding proteins with diverse functions, a large family of ~45 encoding apparently redundant 
keratin associated proteins, and several provisionally annotated microRNA (Gardiner, 2014). The 
comparative analysis of the chromosomes of human and laboratory mice revealed that the long arm 
of HSA21 is homologous to portions of three mouse chromosomes (Mmu): Mmu10, Mmu16 and 
Mmu17. The internal part of Mmu10 contains ~40 protein coding genes, the distal end of Mmu16 
contains ~100 HSA21 orthologous protein coding genes and the internal part of Mmu17 contains 
~20 protein-coding genes (Antonarakis, 2017; Das, 2011; Gardiner, 2014; Rueda, 2012). Two kinds 
of mouse models have been developed for investigating the molecular genetics of DS, trisomic and 
transgenic mouse models. Trisomic mouse models carry complete or segmental trisomy for Mmu10, 
Mmu16, Mmu17 and are able to mimic the genetic complexity of trisomy. Transgenic mouse 
models, on the contrary, have been generated to study the effect of cell-specific and stage-specific 





Fig. 6. Trisomic and transgenic mouse models of DS and their syntenic regions on HSA21. Human chromosome 21 is 
depicted at the top of the figure, with the mouse genome orthologus region found on Mmu10 (red), Mmu16 (orange), 
Mmu17 (light green). A few known genes that are homologous to HSA21 genes in the DS critical region are listed below 
each chromosome. The transchromosomic Tc1 mouse model is shown in dark green, with deletions and a duplication 
(double bar) relative to HSA21 depicted. Below, the segment of the DS critical region encompassed in different mouse 
models for DS is illustrated. From (Herault, 2017).  
In the table below the most popular mouse models of DS generated during the last 30 years are 
briefly described. For more details the reader can refer to several reviews (Hamlett, 2015; Das, 2011; 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table.1. Mouse model of DS. List of trisomic and transgenic mouse model of DS. 
 
None of the mouse models of DS is able to fully replicate the trisomic human phenotype. To 
overcome this obstacle, a full trisomic mouse, carrying the duplications spanning the entire HSA21 
syntenic regions has been created. The Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+ has been 
obtained by sequential crossing of three different trisomic mice the Dp16, Dp17 and Dp10 (Yu, 
2010). Unfortunately, the breeding of this mouse is time consuming and expensive, two generations 
of breading are required to obtain each mouse and final yields are much lower than expected. 
Consequently, for preclinical evaluation with behavioral testing, the generation of a sufficient 
number of mice is impracticable for most laboratories (Gupta, 2016).  
 
The Ts65Dn mouse model of DS  
 
In this work we have exploited the most widely used mouse model of DS, the Ts65Dn. The Ts65Dn 
mouse was created from the translocation of the distal region of Mmu16 onto the centrometer of 
Mmu17. This region of Mmu16 covers the genes Mrpl39 to Zfp295 and contains 132 genes 
orthologous to HSA21 (Davisson, 1990). It must be noted that the Ts65Dn carries three copies of an 
extra segment (arising from Mmu17) with non-DS related genes, including ∼35 protein-coding 
genes, 15 non-protein-coding genes and 10 pseudogenes (Herault, 2017). Thus, some of these genes 
may contribute to the phenotypic impairment of this strain. A detailed characterization of the 
Ts65Dn mouse model revealed several phenotypes similar to those seen in human trisomy 21. These 
mice show craniofacial abnormalities, reduced somatic growth, delayed brain development, and 
defective brain growth and maturation. In addition, this model shows age-related atrophy and 
degeneration of the basal forebrain cholinergic neurons which resembles the neuropathology of 
Alzehimer disease that is frequently observed in people with DS (Aziz, 2018; Bartesaghi, 2011; 
Dierssen, 2012; Duchon, 2011; Rueda., 2012; Stagni, 2018a). 
 
Neuroanatomical alterations of the prenatal brain in the Ts65Dn mouse 
 
Ts65Dn embryos are characterized by a reduction in body and brain weight in comparison with 
euploid littermates. Data regarding brain volume during embryonic development are inconsistent. 
It has been reported that at E13.5, E14.5, and E16.5 Ts65Dn mice have a reduced medial-lateral 
length of the telencephalon (Chakrabarti, 2007), while a study from Aziz et al. found no difference 
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in the mediolateral brain length but a decrease in rostro-caudal brain length at P15.5 (Aziz, 2018). 
Moreover, Ts65Dn mice from E13.5 to E18.5 show a reduced thickness of the intermediate zone, 
which contains migrating neurons and axon tracts, of the sub-plate/cortical plate (SP/CP), 
containing migrating and differentiating neurons, but no differences in the thickness of the VZ and 
SVZ, which contain neural precursor cells. At E18.5 Ts65Dn mice recover the brain weight and the 
size defects of the telencephalon; in addition, all neocortical layers have the same thickness in 
Ts65Dn and euploid mice, indicating a probable delay during early brain development (Chakrabarti, 
2007).  
During the prenatal period, a widespread reduction of 5-Bromo-2-deoxyuridine (BrdU)-positive cells 
in the pallium of Ts65Dn embryos, a poor generation of neurons by the germinal zone, an abnormal 
migration of new generated neurons into the SP/CP, and a reduction in the size of the pyramidal 
cell layer of the CA1 hippocampal region have been reported (Chakrabarti, 2007). In contrast with 
the impaired neurogenesis observed in the neocortex of Ts65Dn embryos, the neuronal precursors 
located in the MGE, a region that produces inhibitory neurons, exhibit faster proliferation rate. This 
is of particular interest because it shows that proliferation defects, in the developing trisomic brain, 
do not involve all brain regions and may provide an explanation for the largest inhibitory weight 
observed in Ts65Dn mice (Chakrabarti, 2010). No difference in the number of apoptotic cell has 
been found during the prenatal period in the neocortex of Ts65Dn (Chakrabarti, 2007). 
       
 
Fig. 7. The embryonic brain of Ts65Dn mice. A. Hypotrophy of the Ts65Dn forebrain at midgestation (E14.5) (scale bar 
1 mm). B. Nissl- stained images of coronal sections from euploid (upper part) and Ts65Dn (lower part) mice taken from 
matched sections at the levels of the future sensorimotor cortex from E13.5 to E18.5 (scale bar 200µm). E= embryonic 






Neuroanatomical alterations of the postnatal brain in the Ts65Dn mouse 
 
Infancy. 
Data regarding differences in brain weight and volume between euploid and Ts65Dn mice during 
the early postnatal period are contradictory. According to some studies, Ts65Dn mice have a 
reduced brain weight at P2 and P15 compared to euploid mice (Guidi, 2014; Stagni, 2016). On the 
contrary, other studies do not report differences between Ts65Dn mice and euploid littermates at 
P8, P15 and P22 (Belichenko, 2004; Bianchi, 2010; Chakrabarti, 2007). Moreover, while some studies 
show that Ts65Dn mice have differences in the volume of the DG at P2 and P15, and in the size of 
cerebellum at P2, P6, P14 (Contestabile, 2007;Contestabile, 2008; Roper, 2006), other studies report 
no volume defects in the cortex, DG, striatum and cerebellum at P2, P6, P10 and P22 (Belichenko, 
2004; Holtzman, 1996; Lorenzi, 2006). The reason for these discrepancies may be related to the use 
of different protocols for brain excision, and/or differences in the number and sex of animals used, 
and/or different quantification methodologies (Stagni, 2018). 
One hallmark of the Ts65Dn mouse model in the perinatal period is the widespread brain cell paucity 
associated with proliferation deficits (Stagni, 2018). At P2, this mouse model exhibits a reduced 
cellularity in the neocortex, DG, hippocampus, striatum, thalamus, hypothalamus, mesencephalon 
and in the Purkinje cell layer, external and internal granular layer of the cerebellum (Contestabile, 
2007; Guidi., 2014; Roper, 2006). A reduced cellularity in the DG has been documented also at later 
stages, P6 and P15 (Bianchi, 2010; Lorenzi, 2006), and a lower number of neurons has been observed 
in the perirhinal cortex at P15 (Roncacé, 2017). 
At P0 Ts65Dn mice show a reduced mitotic potency of the cerebellar granule precursors. At P2, 
Ts65Dn mice have fewer BrdU-positive cells in the neocortex, SVZ, DG, striatum, thalamus, 
hypothalamus, mesencephalon, pons and in the external granular layer of the cerebellum compared 
to the euploid littermates (Contestabile, 2009; Guidi, 2014). Deficits in proliferating cells have been 
observed at P15 in the striatum, neocortex, SVZ and DG (Bianchi, 2010; Contestabile, 2009), while 
at P6 and P30 reductions in proliferating cells are found only in the DG and in the cerebellar granular 
layer (Contestabile, 2009; Roper, 2006). The defective proliferation potency observed in the brain 
of Ts65Dn mice has been attributed to an elongation of the cell cycle, with the G1 and G2 phases 
being those mainly impaired (Contestabile, 2009).  
A reduced number of glutamatergic neurons in the neocortex and a concomitant increase in the 
number of inhibitory interneurons both at cortical levels and in the hippocampal field CA1 has been 
demonstrated in P8 and P15 Ts65Dn mice (Chakrabarti, 2010). At variance with other brain regions, 
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no differences have been observed in the number or size of the basal forebrain cholinergic neurons 
at P2, P10, P22 (Holtzman, 1996), indicating that defects in this brain region arise later during the 
development of Ts65Dn mouse brain.  
Conflicting results have been reported regarding apoptosis in different brain areas of Ts65Dn pups. 
An increased apoptotic death has been found in the cortex at P0 (Lu, 2012) and in the external 
granular layer of the cerebellum at P2 ( Contestabile, 2009). In contrast, no difference in the number 
of apoptotic cell has been described in the neocortex, hippocampus, SVZ and cerebellum of young 
mice (Stagni, 2018).  
During early phases of postnatal brain development, defects in dendritic arborization and in spine 
density affect the brain of Ts65Dn mice, similarly to individual with DS. In particular, it has been 
shown that neurons in the DG exhibit a reduced spine density at P12, P15, and P21 (Belichenko, 
2004; Stagni , 2017) and a reduced number of dendritic branches at P15 (Emili et al., 2020). 
Adolescence  
At P45 Ts65Dn mice have a reduced brain weight when compared to controls in addition to a 
reduced volume of the neocortex, DG, hippocampal fields CA1 and CA3, and cerebellum (Bianchi, 
2010; Guidi, 2014). The defects in cytoarchitecture and the reduced number of proliferating cells 
displayed in early infancy by Ts65Dn pups are retained in adolescent mice. In particular, there is 
evidence for a lower number of granule cells in the DG and a reduce thickness of the terminal field 
of mossy fibers in hippocampal field CA3 (Bianchi, 2010; Stagni, 2013). In addition, P30 and P45 
Ts65Dn mice have a lower number of Brdu- and Ki67-positive cells in both the DG and SVZ in 
comparison with controls (Bianchi, 2010; Chakrabarti, 2010). In P45 Ts65Dn mice, the granule 
neurons of DG have a reduced total dendritic length, a lower branch number and a decreased mean 
length of each branch, in addition to absence of branches of higher order (Guidi, 2014). Moreover, 
the dendritic tree of the pyramidal neurons of hippocampal field CA3 exhibits a reduced number of 
dendritic spines (Stagni, 2013).  
The defects in dendritic architecture that characterize trisomic mice are accompanied by altered 
expression of presynaptic and postsynaptic proteins in the neocortex, DG, and fields CA1 and CA3 
of the hippocampus. In particular, an evaluation of the number of immunoreactive puncta for 
synaptophysin (SYN) (a marker of presynaptic terminal)  and postsynaptic density protein (PSD-95) 
(a marker of postsynaptic terminals) in the brains of Ts65Dn mice aged 45 days demonstrated a 
reduction in the number of immunoreactive puncta (Stagni, 2016). 
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Similarly to individual with DS, Ts65Dn mice show abnormalities in phenotype acquisition, namely a 
reduction in the number of cells that differentiate into neurons and an increase in the number of 
cells with an astrocytic phenotype. Although the absolute number of astrocytes in Ts65Dn and 
euploid mice is similar, Ts65Dn mice have a higher ratio of astrocyte over total cell number, due to 
a reduced number of neurons (Guidi, 2014). 
Adulthood 
Ts65Dn mice aged three months exhibit normal brain weight and volume, normal hippocampal 
volume but a reduction in the DG volume and cerebellar volume, when compared to euploid mice 
(Aldridge, 2007; Holtzman, 1996; Lorenzi, 2006; Necchi, 2008; Olson, 2007). it has been reported 
that mice aged 20-28 weeks have a reduction in the volume of the hippocampal field CA2, but a 
normal volume has been measured in the other regions of the hippocampus (Insausti, 1998).  
The distinctive reduction in cell number that characterizes the brain of the Ts65Dn mouse during all 
developmental stages is also detectable in adult mice. At three months of age, Ts65Dn mice display 
a reduced cell density and a lower number of granule neurons in the DG, but no differences have 
been found in the number of neurons populating the hippocampal fields CA1 and CA3 (Lorenzi, 
2006; Stagni, 2015). A reduction in the number of granule neurons has been also found in older 
mice, aged 20-28 weeks (Insausti, 1998). In Ts65Dn mice aged 2-3 months a significant decrease in 
the density of BrdU- and Ki67-positive cells has been observed in the SVZ, DG and in the motor 
cortex but not in the corpus callosum, a route taken by migratory neurons (Stagni, 2015; Belichenko, 
2011). At 1.5-4.5 months, trisomic mice display a significant cellular reduction in layers V and VI of 
the perirhinal cortex, with a further increase in the damage reported at P15 (Roncacé, 2017). At 8-
10 weeks and 10 months the density of cerebellar granule cells and Purkinje cells is reduced (Olson 
, 2007). Moreover, at 10 months Ts65Dn mice have a normal cerebellar cortical layering but the 
thickness of the molecular layer and granular layer of the vermis are reduced in size (Necchi, 2008). 
Ts65Dn mice aged 4-5 months display a higher density of calretinin-positive cells (inhibitory 
neurons) in the somatosensory cortex compared to the euploid counterparts, suggesting a higher 
level of inhibition (Pérez-Cremades, 2010).  
The defects in dendritic arborization and dendritic spine density observed at P15 and P45 in the DG 
of Ts65Dn mice have been also detected in older mice, aged 3 months and 13-17 months (Dang, 
2014; Stagni, , 2015; Velazquez, 2013). Defects in dendritic arborization have also been found in 
neocortical pyramidal cells of mice aged 10 weeks (Benavides-Piccione, 2004). 
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In line with the reduction in synaptic proteins found in adolescent mice, an alteration in the 
expression of presynaptic and postsynaptic proteins has been reported in the brain of Ts65Dn mice 
aged 3 months (Fernandez, 2007). Ts65Dn mice exhibit an increased colocalization of synaptophysin 
with the inhibitory presynaptic proteins GAD65 and VGAT, suggesting an increase in the inhibitory 
weight (Belichenko, 2007). In agreement with the synaptic alterations found in the trisomic brain of 
Ts65Dn mice, long term potentiation (LTP) in the hippocampal DG (Kleschevnicov, 2004) and in the 
perirhinal cortex (Roncacé, 2017) is severely impaired.  
Data regarding the increased number of astrocytes in the hippocampal region of adult Ts65Dn are 
inconsistent. A larger number of astrocytes has been reported in the hippocampus of 3 months old 
Ts65Dn mice in comparison with euploid mice, although this difference did not reach statistical 
significance (Holtzman, 1996). However, another study shows that Ts65Dn mice aged 4 months have 
a lower percentage of Brdu/GFAP-positive cells (cells that had acquired an astrocytic phenotype) in 
the DG when compared with euploid mice (López-Hidalgo, 2016). Finally, cell culture experiments 
show that Ts65Dn oligodendrocytes exhibit impaired maturation and lower viability, in agreement 
with the defect in myelination observed in fetuses and children with DS (see(Olmos-Serrano, 2006)). 
In addition to the neurodevelopmental defects reported above Ts65Dn mice undergo age-related 
neurodegeneration. The proliferation potency and cellularity defects seen in the SVZ and 
hippocampus of Ts65Dn mice is observed also at older ages, suggesting that these defects 
characterize the Ts65Dn mice brain during the whole life span (Corrales, 2014; López-Hidalgo, 2016; 
Martínez-Cué, 2013). Ts65Dn mice aged 14 months show a reduction in the number of BrdU-positive 
cells in the SVZ and RMS (Guidi, 2016). In 5-8 month-old Ts65Dn mice, the number of basal forebrain 
cholinergic neurons is reduced (Ash, 2014; Contestabile, 2006; Cooper, 2001). During aging, Ts65Dn 
mice exhibit low brain levels of choline acetyltransferase, neurotrophic growth factor, neurotrophic 
tyrosine kinase receptor type 1 in the basal forebrain cholinergic neurons, and loss of tyrosine 
hydroxylase in the locus coeruleus. These defects are relevant to premature cognitive decline and 
development of AD (Kelley, 2016; Rueda, 2012). 
 
Behavioral alterations during the life span of the Ts65Dn mouse model  
 
The distinctive alterations in the brain of Ts65Dn mice during the whole life span translate into 
functional alterations and behavioral impairments starting from early life stages. Similarly to the 
hypotonia and delay in achieving developmental milestones found in newborns with DS, Ts65Dn 
pups exhibit deficits in achieving both early and late developmental milestones in the open field and 
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motor-based developmental task. Ts65Dn perform worst in surface righting, negative geotaxis, cliff 
aversion, open field and air righting task compared with euploid littermates. However, they exhibit 
a similar performance in the forelimb grasp, ear twitch, eye opening and auditory startle responses 
(Aziz, 2018).  
Young adult and adult mice show significant hyperactivity in setting that elicit caution and lack of 
movement in euploid animals, such as the open field and plus maze tests, but do not exhibit deficits 
in sensory capabilities and coordinated behavior, i.e. olfactory sensitivity, visual abilities, orienting 
reactions, forelimb strength, postural skills, coordination, climbing, locomotion, motor coordination 
and balance deficits (Bartesaghi 2011; Rueda, 2012). However, Ts65Dn mice perform worst in 
learning an operant conditioning paradigm and in tests that require the integrity of the hippocampal 
system such as spontaneous alternation (T maze), contextual memory (fear-conditioning test), 
spatial learning, long-term memory and cognitive flexibility (Morris water maze test; radial arm 
maze test), non-spatial short- and long-term declarative memory (novel object recognition) (see 
(Bartesaghi, 2011; Rueda, 2012)). This evidence suggests that in Ts65Dn mice, similarly to individuals 
with DS, declarative memory which, in rodents is delineated along spatial and recognition memory 
domains, is impaired. Furthermore, it is important to note that, similarly to humans with DS, the 
Ts65Dn mouse shows a cognitive decline with age (Hunter, 2003), indicating a strong correlation 
with the onset of AD-like pathology.  
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THERAPIES FOR DS  
 
In the last two decades the number of studies focusing on pharmacotherapies for DS has grown 
exponentially (Stagni, 2015). The knowledge of the gene content of HSA21, the efforts to 
understand signaling, metabolic and developmental pathways that are dysregulated in DS, the 
availability of several mouse models that mimic DS, the generation of trisomic human pluripotent 
stem cells (iPSCs) and their differentiation in various cell types and tissue, the awareness of the 
numerous neurodevelopmental alterations that affect the DS brain has made possible a cautious 
enthusiasm for attempting to treat individuals with DS using drugs that appear to be effective in DS 
mouse models (Antonarakis, 2017; Antonarakis, 2020). However, most of the pharmacological 
attempts to improve trisomy-related brain defects were conducted in adult mice. It is important to 
note that neurodevelopmental defects in DS (and Ts65Dn mice as well) are already present at fetal 
life stages (Stagni, 2015). In view of the time course of brain development neonatal and, even better, 
prenatal therapies can have the largest impact. Early therapeutic interventions may be able to 
potentially affect the development of the whole brain, exerting widespread effects in terms of the 
phenotypic features they are able to rescue and of the duration of their effects (see (Stagni, 2015)). 
The Ts65Dn mouse model has been extensively exploited for preclinical studies of experimental 
pharmaceutical therapies during all developmental stages, from prenatal intervention to therapies 
targeted to the comorbidity between DS and AD. This section will focus on neonatal and prenatal 
therapies in the Ts65Dn mouse model of DS, with a specific section dedicated to therapies with 
natural compounds. For a detailed description of preclinical studies in the Ts65Dn mouse at adult 
life stages (summarized in Table 2) the reader can refer to several  comprehensive reviews 







Table. 2. Therapies administered at adult life stages in the Ts65Dn mouse model of DS. The outcome “Rescued” means 
that in treated Ts65Dn mice the examined phenotype became similar to that of untreated euploid mice. The outcome 
“Improved” means that in Ts65Dn mice treatment ameliorated but did not rescue the examined phenotype. The text in 
bold in the column “Outcome” highlights treatments that were ineffective (Failed) and the text in bold in the column 
“Long-term effect” highlights treatments that either had (Yes) or did not have (No) a long-term effect. ADNF, Activity 
Dependent Neurotrophic Factor; ADNP, Activity Dependent Neuroprotective Protein; BM, Barnes Maze; CFC, Contextual 
Fear Conditioning; CNTF, Ciliary Neurotrophic Factor; d, day; DG, dentate gyrus; m, month; MWM, Morris Water Maze; 
NA, not available; NOR, Novel Object Recognition; NPR, Novel Place Recognition; PM, Plus Maze; SA, Spontaneous 







NEONATAL THERAPIES IN THE Ts65Dn MOUSE MODEL  
 
Therapies targeted to transmitter systems 
 
Fluoxetine 
Fluoxetine is an antidepressant belonging to the selective serotonin reuptake inhibitor class. 
Fluoxetine inhibits the serotonin transporter and thus retards the reuptake of 5-HT and in this way 
the neurotransmitter can persist longer in the synaptic cleft enhancing its action on the postsynaptic 
neuron. Neonatal treatment with fluoxetine in Ts65Dn mice from P3 to P15 restored number of 
proliferating cells in the DG, total number of granule cells, dendritic pattern, and hippocampal 
connectivity. Furthermore, one month after treatment cessation Ts65Dn mice showed normal 
learning in hippocampus dependent memory (Bianchi, 2010; Guidi, 2013; Stagni, 2013). In a 
subsequent study it has been found that adult mice (3.month-old) treated neonatally with 
fluoxetine exhibit restored hippocampal neurogenesis, no dendritic pathology and restored 
hippocampus dependent memory (Stagni, 2015). 
Clenbuterol  
Clenbuterol is a long-acting β-adrenergic agonist, clinically used as a bronchodilator. A recent study 
that examined the effects of neonatal treatment with β-adrenergic agonists in the Ts65Dn mouse 
model showed that trisomic mice treated with clenbuterol (from P3 to P15) have increased 
proliferation rate of granule precursor cells, restoration of granule cell density, and a complete 
rescue of dendritic pathology, in terms of dendritic complexity and spine density, in DG granule 
neurons (Emili, 2020).  
Salmeterol  
Salmeterol is a long-acting β-adrenergic agonist. The same study mentioned above (Emili, 2020) also 
examined the effect of salmeterol. Ts65Dn mice treated in the neonatal period (from P3 to P15) 
with salmeterol did not exhibit an increase in neurogenesis but exhibited increased spine density, 
increased dendritic length and increased number of branches of granule neurons, when compared 
to the untreated counterparts (Emili, 2020). A comparison of the effects of clenbuterol and 





Therapies targeted to perturbed signaling pathways  
 
SAG 1.1 
SAG 1.1 is a derivative of chlorobenzo [b] thiophene, which was identified as a Sonic hedgehog 
agonist. A single dose of SAG 1.1 in P0 Ts65Dn mice rescued at P6 the number of cells in the granule 
cell layer of the cerebellum, and this positive effect was still present after 4 months. Moreover, SAG 
was able to restore hippocampal LTP and enhance Ts65Dn mice performance in hippocampal 
dependent memory test (Das, 2013). 
ELND006  
ELND006 is a selective inhibitor of the γ-secretase enzyme and thereby it reduces the formation of 
amyloid precursor protein intracellular domain (AICD), a small peptide deriving from the processing 
of APP that negatively affects neurogenesis. Treatment with ELND006 in Ts65Dn neonate (P3-P15) 
was able to restore neurogenesis in SVZ and DG, number of granule cells, synapse development, 
and lowered the level of various gene transcriptionally regulated by AICD (Giacomini, 2015). 
Furthermore, one month after treatment cessation the pool of proliferating cells in the DG, the total 
number of granule neurons as well as the number of pre- and postsynaptic terminals in the stratum 




Cyclosporin A  
Cyclosporin A (CASA) is an FDA approved immunosuppressant. A recent study demonstrated that 
neonatal treatment (from P3 to P15) with CSA in Ts65Dn mice was able to restore proliferation of 
neuronal precursors cells in SVZ and SGZ, total number of hippocampal granule cells and dendritic 
spines of granule neurons (Stagni, 2019).  
PRENATAL THERAPIES IN THE Ts65Dn MOUSE MODEL 
 
Therapies targeted to transmitter systems 
 
Choline  
Choline is a vitamin-like nutrient and a precursor of acetylcholine, a fundamental brain 
neurotransmitter. Several studies investigated the effects of maternal choline supplementation in 
Ts65Dn mice. Pregnant dams were treated with an enriched choline diet (4.5-fold than normal) 
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throughout pregnancy and until litters weaning. In the adult offspring choline supplementation was 
able to restore hippocampal neurogenesis, reduce the loss of BFCNs and rescue learning and 
memory impairment in hippocampal dependent spatial cognition (Ash, 2014; Kelley, 2015; Moon, 
2010; Velazquez, 2013). Moreover, maternal choline supplementation was able to normalize adult 
offspring gene expression, in particular it was able to regulate aberrant expressions of genes 
involved in GABAergic neurotransmission, endosomal-lysosomal pathways, autophagy and kinase 
activity in CA1 pyramidal neurons (Alldred, 2019). Another study with maternal choline 
supplementation demonstrate that treatment was able to normalize the expressions of aberrant 
genes related to the cytoskeleton, AD, cell death, presynaptic function, immediate early, G protein 
signaling and cholinergic neurotransmission in BFCN (Kelley, 2019). 
 
Fluoxetine  
Based on the strong a positive effect of neonatal treatment with fluoxetine on brain development, 
pregnant Ts65Dn female were treated with fluoxetine from E10 to delivery. At P2 the offspring 
exhibited restored neurogenesis and cellularity throughout the forebrain, midbrain, and hindbrain. 
Importantly, at P45 the prenatally-treated mice exhibited restored number of proliferating neuronal 
precursors, normal number of pre- and postsynaptic terminals, no deficits in dendritic arborization 
and restoration of cognitive performances (Guidi, 2014). 
 
Therapies targeted to perturbed signaling pathways  
 
Cilostazol 
Cilostazol is a selective inhibitor of phosphodiesterase (PDE) 3 that promotes the clearance of 
amyloid b and it has been demonstrated to rescues cognitive deficits in an AD mouse model (Maki, 
2014). A recent study showed that early intervention (from pregnancy to adulthood) with cliostazol 






Neuropeptides are small proteinaceous substances produced and released by neurons and acting 
on neural substrates. Two active peptides derived from the neurotrophic factors activity-dependent 
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neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF), NAPVSIPQ 
(NAP) and SALLRSIPA () respectively, have been administered to pregnant dams from E8 to E12. 
Ts65Dn offspring treated prenatally achieved developmental milestones at the same time as euploid 
littermates. In addition, prenatal treatment prevented the activity-dependent neurotrophic factor 
decrease and the downregulation of glial fibrillary acidic protein in the TS65Dn brains (Toso, 2008). 
Furthermore, adult Ts65Dn mice treated prenatally showed increased levels of NMDA receptor 
subunits NR2A and NR2B and of GABA receptor subunits GABA Aβ3 (Vink, 2009) and performed 
better in a hippocampus-dependent memory test (Incerti, 2012). 
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CLINICAL TRIALS IN DOWN SYNDROME  
 
Pharmacological studies in people with DS began in the 1960s. Early studies were often based on 
case reports and were typically small, single-center trials, sometimes open label, making it difficult 
to assume valid conclusions regarding their efficacy (Hart, 2017). Clinical trials in DS initially focused 
on AD and successively moved to investigate early pharmacological interventions and to target the 
pediatric population. The exploiting of translational research and, in particular the usefulness of the 
Ts65Dn mouse model for the study of DS, made it possible to target specific molecular mechanisms 
within the brain and to address cognitive and functional deficits associated with DS (Hart, 2017). 
The majority of the clinical trials carried out in people with DS showed moderate to no effects. It 
must be observed that in the history of clinical trials in DS the majority of studies conducted so far 
have focused on adolescent or adult population (see table 2). While the initial focus on this age 
range is required to establish the safety of a pharmacological intervention, these studies have had 
a limited success in demonstrating their efficacy. This emphasize the need of studying the potential 
effects of early pharmacological intervention on brain development and cognitive outcome in 
infants with DS (Hart, 2017). It has been well established that an early pharmacotherapeutic 
intervention is capable to rescue brain developmental defects in mouse model of DS. Considering 
the timeline of human brain development when acting on prevention it is necessary to exploits the 
windows of opportunity of the developing brain to improve the neurodevelopmental alterations 
that characterize the DS brain (Stagni, 2015).  
 
The table below summarizes registered clinical trials using pharmacological interventions targeting 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table. 3. Registered clinical trials in DS.  
PRECLINICAL AND CLINICAL STUDIES WITH NATURAL COMPOUNDS 
This section is focused on neonatal and prenatal preclinical studies and on clinical trials exploiting 
natural compounds to target specific aspects of the trisomic brain  
 
Neonatal therapies with natural compounds 
 
Eppigallocatechin-3-gallate 
Epigallocatechin-3-gallate (EGCG) is a flavonoid present in green tea leaf extracts that, among other 
activities, is able to specifically inhibits DYRK1A. Early postnatal administration of EGCG (from P3 to 
P15) restored hippocampal neurogenesis, total number of granule neurons, and pre- and 
postsynaptic proteins levels in the hippocampus and cortex of Ts65Dn mice. However, one month 
after treatment cessation the effects were no longer present and behavioral testing of hippocampus 
dependent learning and memory showed no improvement, indicating a lack of long lasting effects 
of EGCG (Stagni, 2016). 
7,8-dihydroxyflavone  
7,8-dihydroxyflavone (7,8-DHF) is a natural flavonoid that mimics the action of BDNF because it is 
able to bind with high affinity and specificity the tropomyosin-related kinase receptor B (TrkB). 
Neonatal administration of 7,8-DHF (from P3 to P15) in Ts65Dn mice induced an increase in the 
number of neural precursor cells in the DG, restoration of granule cell number, dendritic spine 
density, and levels of SYN. Moreover, a prolonged treatment from P3 to P50 was able to improve 
learning and memory defects of Ts65Dn mice (Stagni, 2017). However, in another study neonatal 
treatment (from P3 to P15) did not show learning and memory improvement one month after 
treatment cessation, indicating that the positive effects of 7,8-DHF in the trisomic brain do not 
outlast the end of the treatment.  
 
Prenatal therapies with natural compounds  
 
Epigallocatechin-3-gallate 
Epigallocatechin-3-gallate (EGCG) a flavonoid that showed interesting results when administered 
postnatally in Ts65Dn mice, was also tested prenatally. Treatment with EGCG from gestation to 
adulthood was able to suppress an imbalanced expression of an alternative splicing product of tau, 
regulated by DIRK1A, and to rescue anxiety and memory deficits in Ts65Dn adult mice (Yin, 2017). 
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Moreover, it has been shown that prenatal treatment with EGCG at E7 and E8 was able to modulate 
deficiencies in neural crest cells, peripheral nervous tissue ,and to normalize craniofacial 
phenotypes in the Ts65Dn mouse model of DS (McElyea, 2016). 
α-Tocopherol  
α-Tocopherol is the most active biological form of vitamin E. α-Tocopherol enriched diet was 
administered to pregnant Ts65Dn dams during the entire pregnancy and lactation period, and to 
the newborn until 12 weeks of age. The chronic supplementation of vitamin E was able to increase 
the granule cells density, to reduce the products of lipidic peroxidation in the DG, to reduce anxiety 
levels and to improve spatial learning and memory in Ts65Dn mice (Shichiri, 2011). 
Oleic acid  
Oleic acid is a monounsaturated acid of the ω-9 series. It is present endogenously in the organism 
and can also be obtained from the diet. Pregnant Ts65Dn female were treated from E10 to P2 with 
oleic acid and the outcome was examined in the progeny at P2 and at P30.P45. Administration of 
oleic acid increased the volume of the granule cell layer, the number and density of granule cells 
and the number of proliferating cells in the DG of P2 Ts65Dn mice. Moreover, prenatally treated 
mice tested at P30-P45 showed better cognitive abilities, as assessed with the Morris Water Maze 
test, and a higher density of PSD95 (García-Cerro, 2020).  
Linolneic acid  
α-Linolenic acid is an essential polyunsaturated fatty acid (PUFA) of the ω-3 series, which has to be 
obtained from the diet. The same study mentioned above (García-Cerro, 2020) also examined the 
effects of prenatal treatment with linolenic acid. Pregnant Ts65Dn female were treated from E10 to 
P2. At P30-45 Ts65Dn mice treated prenatally demonstrated higher density of PSD95 and better 
learning and memory performances compared to the untreated counterpart (García-Cerro, 2020).  
 
Clinical trials with natural compounds  
 
Epigallo-catechin-3-gallate (EGCG) is a flavonoid derived from green tea leaves and a well know 
DYRK1A inhibitor. A randomized, placebo-controlled pilot study tested the effects of green tea 
extract with a mean EGCG oral dose 9 mg/kg/day on cognition in adolescent with DS and found that 
three months of treatment with green tea extracts is effective in improving recognition and working 
memory (De la Torre, 2014) (ClinicalTrials.gov identifier NCT01394796). A phase II clinical trial in 
adolescent with DS, with an association therapy with green tea extracts and cognitive training for 
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12 months, showed a positive effects on visual recognition memory, inhibitory control, and adaptive 
behavior (de la Torre, 2016) (ClinicalTrials.gov identifier NCT01699711). However, phase III clinical 
trial with a larger population is needed to assess the long term efficacy of EGCG and cognitive 
training (Hart, 2017). 
Antioxidants. Mitochondria are the most susceptible target of reactive oxygen species and 
mitochondrial DNA control region mutations occur in individuals with DS who suffer from dementia 
(Lott, 2011). A two-year randomized, double-blind, placebo-controlled clinical trial assessed 
whether a combination of antioxidants and mitochondrial cofactor could lead to stabilization or 
improvement in cognitive functioning in adults with DS and AD-like dementia. However, this study 
determined that antioxidant supplement was ineffective as treatment for dementia in individuals 
with DS and AD (Lott, 2011) (ClinicalTrials.gov identifier NCT00056329). 
Folinic acid, is a vitamer of vitamin B9. As several genes involved in folate metabolism are located 
on HSA21 and folate deficiency has been linked to ID, folinic acid was investigated as 
pharmacotherapy for DS. A randomized control trial in children with DS with an association therapy 
of folinic acid an antioxidant found no effects on brain development and long term communication 
abilities (Ellis, 2008) (ClinicalTrials.gov identifier NCT00378456). More recently, a double-blind, 
placebo-controlled, single center trial in infants with DS who followed a folinic acid therapy revealed 
an improvement in global development. This effect was larger in a sub-analysis of subjects taking 
concomitant thyroid hormone (Blehaut, 2010) (ClinicalTrials.gov identifier NCT01576705). 
However, a recent 4-arm, placebo-controlled trial with folinic acid and thyroid hormone aimed at 
evaluating improvement in psychomotor development in toddlers with DS did not support this 




FLAVONOIDS AND THE BRAIN  
 
Flavonoids are a large group of polyphenolic compounds containing a basic flavan nucleus with two 
aromatic rings (the A and the B rings) interconnected by a three-carbon-atom heterocyclic ring (the 
C ring). Flavonoids are the most common group of polyphenolic compounds found ubiquitously in 
fruits and vegetables (Perez-Vizcaino, 2018). They are constituted of two aromatic rings, bound 
together by three carbon atoms that form an oxygenated heterocycle. Flavonoids can be subdivided 
into 6 subclasses depending on the structure of the heterocycle: flavonols, flavones, isoflavones, 
flavanones, anthocyanidins, and flavanols (Manach, 2004).  
These molecules are well known for their antioxidant properties, but they are also capable of several 
different beneficial effects on health. Flavonoids are able to reduce cardiovascular diseases and high 
blood pressure and to have antiallergic, anti-inflammatory, hepatoprotective and antidiabetic 
effects (Terahara, 2015). They are currently under investigation for the prevention of cancer and 
chronic diseases through their action as free radical scavenger, the ability to block lipid peroxidation 
chain reaction and the chelating action with metal ions (Terahara, 2015). 
Furthermore, several studies recognized flavonoids as promising plant-based bio actives with 
neuroprotective properties, able to suppress neuroinflammation and potentially improve cognitive 
functions both in animals and humans (Pérez-Hernández, 2016; Rendeiro,2015). They are able to 
ameliorate cerebral arteries vascularization, modulate receptor function and interact with signaling 
pathways for neuronal function and survival, promote the expression of genes and proteins involved 
in synaptic plasticity and neuronal repair, modulate LTP, affect aspects crucial for neuronal 
communication such as spine density, stimulate neuronal regeneration and induce neurogenesis 
(Rendeiro, 2015; Spencer, 2009).  
 
Flavonoids and neuroinflammation  
 
Neuroinflammation is closely related to the pathogenesis of neurodegenerative diseases. The 
majority of events linked to neuroinflammation, such as transcriptional and post-transcriptional 
regulation of inducible nitric oxide synthase (iNOS) and cytokines in activated microglia and 
astrocytes, are controlled by upstream MAPK signaling. Some flavonoids, i.e. quercetin and 
flavonoids present in blueberry, are able to reduce the iNOS expression triggered by 
neuroinflammation, inhibit cyclooxygenase expression, NADPH oxidase activation and reactive 
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oxygen species (ROS) generation, through inhibition of MAPK signaling cascades (Calis, 2019; 
Spencer, 2009).  
 
Flavonoids and neurodegeneration  
 
There is a growing body of evidence suggesting that flavonoids may be able to delay the progression 
of neurodegenerative diseases such as AD and Parkinson’s disease (Spencer, 2009). One example 
are Gingko biloba extracts that protect hippocampal neurons against NO and b-amyloid induced 
neurotoxicity (Luo, 2002). Flavonoids are also effective in blocking oxidant induced neuronal injury, 
modulating protein and lipid kinase signaling cascades such as PI3K/Akt, tyrosine kinase, PKC and 
MAPK signaling pathways (Spencer, 2007; Williams, 2004). Actions on these pathways are able to 
affect neuronal functioning through the phosphorylation of target molecules changing caspase 
activity and/or gene expression. Moreover, some flavonoids such as hesperetin and its active 
metabolites are able to inhibit oxidant-induced neuronal apoptosis through the activation of pro-
survival pathways and inhibition of pro-apoptotic pathways (Spencer, 2009).  
 
Flavonoids and learning and memory  
 
Several lines of evidence suggest that fruits and vegetables-derived flavonoids are capable to 
promote beneficial effects on learning and memory (see (Spencer, 2009)). Although the precise site 
of their interaction with signaling pathways remains unknown, they are able to act in numerous 
different ways; binding to ATP sites on enzymes and receptors, modulating kinases activity, affecting 
the function of phosphatases, preserving Ca2+ homeostasis and preventing Ca2+-dependent 
activation of kinases in neurons, modulating transcription factor activation and binding to promoter 
sequences (Spencer, 2009). Through these actions flavonoids are able to induce morphological 
changes that can influence memory acquisition, consolidation and storage, i.e. the flavonoid 
induced improvement in neuronal spine density and morphology, two crucial factors for learning 
and memory (Spencer, 2009). Flavonoids are well known for their ability to prevent cerebrovascular 
diseases, including those associated with stroke and dementia (Commenges, 2016). Efficient 
cerebral blood flow is vital for optimal brain functioning. Flavonoids trough their action on 
endothelial function and peripheral blood flow, are able to increase cerebrovascular blood flow and 
consequently brain functions. Moreover, flavonoids vascular action seems to facilitates adult 
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hippocampal neurogenesis, the new hippocampal cells clustered near blood vessels proliferate in 
response to vascular growth factors (Spencer, 2009). 
7,8-DIHIDROXYFLAVONE 
 
The 7,8-dihydroxyflavone (7,8-DHF) is a flavone substituted by hydroxy groups at positions 7 and 8. 
It is naturally present in Godmania aesculifolia, Tridax procumbens and the primula leaves. This 
flavonoid was identified as a high affinity TrkB agonist among 2000 biologically active compounds 
by screening of the Spectrum Collection Library (Jang, 2010). 7,8-DHF is able to cross the BBB, bind 
TrkB receptor, provokes receptor dimerization, phosphorylation and activation of its downstream 
signaling cascades. Structural-activity relationship (SAR) study suggests that the catechol group is 
essential for 7,8-DHF activity, in particular the presence of 8-hydroxy group in the A ring is necessaryl 
for the TrkB stimulatory effect (Liu, 2010).  
 
Fig.8. 7,8-dihydroxyflavone chemical structure. From (X. Liu et al., 2010). 
 
Pharmacology of 7,8-DHF  
 
The in vivo investigation of 7,8-DHF pharmacokinetics profile determined that 7,8-DHF in mice has 
a half-life of about 134 min in plasma after oral gavage of 50 mg/Kg (which is 10-fold the widely 
used therapeutic dose). The plasma concentration peaked at 10 min with 70 ng/ml and was still 
detectable after 8 hours (5 ng/ml). 7,8-DHF is able to cross the BBB and the brain concentration 
peaked at 10 min with a 50 ng/g, at 4 hours is 7 ng/g and at 6 h is below the quantitative limits (Liu, 
2013). 7,8-DHF, as all the catechol-containing compound undergo glucuronidation, sulfation and 
methylation. From chromatographic analysis of plasma samples major metabolites were detected 
in addition to the parent drug including 7-metoxy-8-hydroxyflavone (7M8H-flavone), 7-hydroxy-8-
metoxyflavone (7H8M-flavone). The in vivo agonistic effects exerted by 7,8-DHF might mainly result 
from the activity of 7,8-DHF and its metabolite 8M7H-flavone (Liu, 2013). The plasma concentration 
of both the methylated metabolites are low compared to the parent compound suggesting that 
glucuronidation but not methylation may be that main metabolic route. Moreover, 8M7H-flavone 
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possess higher half-life compared to the 7M8H-flavone, indicating that 8M7H-flavone is more 
metabolically stable (Liu, 2013). The oral administration of 7,8 DHF in mice elicits robust TrkB 
activation, suggesting that this molecule is orally-bioavailable (Liu, 2010). Both the methylated 7,8-
DHF metabolites are able to activate TrkB receptor in the mouse brain and in primary neurons (Liu, 
2013). However, the presence of the catechol group makes 7,8-DHF susceptible to fast metabolism, 
including sulfation, glucuronidation, methylation (Liu,2012). For this reason several prodrugs of 7,8-
DHF has been synthetized and tested in order to improve the bioavailability of the parent drug.  
In vitro experiment showed that 7,8-DHF treatment did not inhibit human embryonic kidney 
(HEK)293 cells proliferation at a dose up to 50 μM. However, at 100 μM 7,8-DHF it exerted an 
antiproliferative effect. Neuronal cell death assay revealed that 7,8-DHF is non-toxic for primary 
cortical neurons up to 5 μM (Liu, 2010). An in vivo study showed no pathological changes induced 
by 7,8-DHF in kidney, liver, lung, muscle, spleen, cortex, hippocampus, heart, intestine and testis in 
mice treated with 5 mg/kg/day for 3 weeks compared to the vehicle treated counterparts (Liu, 
2010). Moreover, from complete blood count (CBC) analysis there was no difference between 7,8-
DHF-treated and control mice (Liu, 2010). This is consistent with the results of another long-term 
experiment where female mice receiving ~ 2.4 μg 7,8-DHF/day for 20 weeks displayed normal CBC 
values (Chan, 2015). Additionally, 5 mg/kg/day treatment in neonate and young mice did not induce 
side effects on the body weight (Stagni, , 2017). Taken together these data in mice show that chronic 
treatment with 7,8-DHF does not exert toxic effects.  
 
The TrkB receptor 
 
The binding of BDNF to the TrkB receptor, causes receptor dimerization and autophosphorylation 
of the intracellular tyrosine residues (Y705/6), the formation of the phosphorylated-TrkB receptor 
(Rantamäki, 2019) and BDNF/Trk receptor complex translocation toward cellular membrane lipid 
rafts (i.e., microdomains rich in cholesterol and sphingolipids) (Suzuki, 2004). Thus, ligand-induced 
TrkB translocation into lipid rafts represents a signaling mechanism selective for synaptic 
modulation by BDNF in the central nervous system (Suzuki, 2004). Phosphorylated-TrkB leads to 
activation of three interconnected intrinsic intracellular cascades (Cunha, 2010 ; Chao, 2003) 
Phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and phospholipase 
Cγ (PLCγ) (Gonzalez, 2016; Huang, 2003; Minichiello, 2009).  
The TrkB receptor is capable of autophosphorylation and activation of downstream cascades 
independent of its ligand (BDNF). Activation of TrkB receptors in the absence of BDNF occurs via 
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trans-activation mechanism, which involves specific G protein coupled receptors (GPCR), such as 
the A2α adenosine receptor (A2αR) (Pradhan, 2019). In addition to TrkB transactivation by A2aRs, 
the transactivation of TrkB also occurs via other mechanisms such as epidermal growth factor, 
dopamine 1 receptors, pituitary adenylate cyclase-activating polypeptide, H2O2, and zinc (Huang, 
2008). 
 
7,8DHF- TrkB- dependent signaling 
 
Similarly to BDNF 7,8-DHF specifically binds the TrkB receptor extracellular domain, in a different 
site in comparison with BDNF, with a binding constant Kd of =320 nM. It acts as a selective TrkB 
agonist, mimicking the physiological actions of BDNF (Jang, 2010; Liu, 2014).  
7,8-DHF induces TrkB phosphorylation at Tyr515, Tyr706, and Tyr816 (X. Liu et al., 2014). The 7,8-
DHF induced phosphorylation of TrkB leads to activation of several pathways, MAPK, PI3/Akt, and 
ERK1/2 in a time frame that comparable to BDNF and in a dose-dependent manner (Jang, 2010; Liu, 
2016; Liu, 2010, 2014, 2013). After receptor internalization, the formation of signaling endosomes 
and ubiquitination/degradation had an important role in signal transduction. The action of BDNF in 
stimulating TrkB internalization and early endosomes delivery in the first 10 min is more potent than 
7,8-DHF. On the contrary 7,8-DHF produces a more robust endocytic response at 60 minutes. TrkB 
ubiquitination by BDNF occurs 10 min after stimulation and its ubiquitination signals correlates with 
its phosphorylation pattern. While BDNF-induced TrkB phosphorylation peaks at 10 min, decreases 
at 60 min and ended at 180 min, 7,8-DHF-triggered TrkB phosphorylation lasts for more than 3 h, 
without inducing TrkB ubiquitination or degradation ( Liu, 2014). These findings support the idea 
that bot 7,8-DHF and BDNF activate TrkB but different mechanisms and a different time-course.  
 
7,8 DHF-TrkB independent signaling 
 
A recent study in cell assays failed to confirm that 7,8-DHF activates the TrkB receptor (Boltaev, 
2017). This discrepancy may be due to the use of different cell model, culture condition and duration 
of treatment. However, it must be taken into account that 7,8-DHF may induce transactivation of 
the TrkB receptor without binding to it. Different studies suggest that some effects of 7,8-DHF, in 
particular the antioxidant effects, do not require the TrkB receptor (see(Barriga, 2017; Ryu, 2014; 
Huai, 2014)). In addition, there is evidence for the direct uptake of flavonoids and their metabolites 
into the cytosol of several cell types, including cells of CNS (Ferrara, 2019; Mukai, 2011; Spencer, 
 57 
2004). If this also happen for 7,8-DHF, the cell uptake will provide the possibility of a TrkB-
independent modulation of signalling (Williams, 2004). In addition, as an antioxidant 7,8-DHF might 
exert a direct action within the cell which may contribute to its antioxidant effects (Han, 2014).  
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RATIONALE AND GOAL OF THE STUDY 
 
Intellectual disability and brain hypotrophy are two of the main hallmarks of DS. The reduced brain 
volume typical of infants with DS can be attributed to neurogenesis impairment. Neurogenesis 
defects can be traced back to early gestational periods in fetuses with DS (Stagni, 2018a). Similarly 
to individuals with DS, the brain of Ts65Dn mouse is affected by reduced neurogenesis from early 
embryonic stages and defective neuronal proliferation is retained throughout the whole life span 
(Stagni, 2018a). While most of the brain neurons are generated during the prenatal period, there is 
the notable exception of those in the hippocampal dentate gyrus and cerebellum whose generation 
continues postnatally (Brazel, 2003). Previous studies in the Ts65Dn mouse showed that 
pharmacological interventions during the neonatal period are able to ameliorate the defective 
hippocampal neurogenesis that characterizes DS (Stagni, 2015). Considering that the bulk of 
neurogenesis takes place prenatally, therapeutic intervention aimed at correcting brain 
development should be started during the embryonic period. 
Very few studies have examined the effects of prenatal pharmacotherapy in DS mouse models so 
far. A pioneering study demonstrated that embryonic treatment with fluoxetine was able to restore 
the trisomy-linked defects of brain development in the Ts65Dn mouse model (Guidi, 2014). 
Although prenatal administration of fluoxetine appears to be free of side effects in mice, the use of 
this molecule in humans may pose some caveats. From this perspective, 7,8-DHF, a natural molecule 
typically present in fruits and vegetables may be an ideal candidate for prenatal treatment. The 
natural flavonoid 7,8-DHF is able to cross the BBB and specifically binds the TrkB receptor activating 
its downstream signaling cascade (Liu, 2010). It has been demonstrated that 7,8-DHF was able to 
promote neurogenesis in the DG of adult mice (Liu, 2010), increase dendritic spine density in various 
rats brain regions among which amygdala, hippocampus and prefrontal cortex (Zeng, 2012), exert 
neurotrophic effects in various developmental disorders (Liu, 2013). Furthermore 7,8-DHF showed 
no side effects on somatic development, which is of particular relevance in the perspective of fetal 
treatment (Stagni, 2017).  
Based on these premises, in this study we wanted to investigate whether prenatal treatment with 









Ts65Dn mice were generated by mating B6EiC3Sn a/A-Ts(17^16)65Dn females with C57BL/6JEiJ x 
C3H/HeSnJ (B6EiC3Sn) F1 hybrid males. This parental generation was provided by Jackson 
Laboratories (Bar Harbor, ME, USA). To maintain the original genetic background, the mice used in 
this study were of the first generation of this breeding. Animals were genotyped as previously 
described (Reinholdt, 2011). The day of birth was designated as postnatal day zero (P0). The animals’ 
health and comfort were controlled by the veterinary service. The animals had access to water and 
food ad libitum and lived in a room with a 12:12 h light/dark cycle. Experiments were performed in 
accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) 
for the use of experimental animals and were approved by Italian Ministry of Public Health. In this 
study, all efforts were made to minimize animal suffering and to keep the number of used animals 
to a minimum. 
 
Experimental protocol  
 
Ts65Dn females (n= 14) were bred with C57BL/6JEi x C3SnHeSnJ (B6EiC3Sn) F1 males (n= 8). 
Conception was determined by examining the vaginal plug. Pregnant females received a daily 
subcutaneous injection of either 7,8-DHF (7,8-DHF, Sigma Aldrich) 5 mg/kg in vehicle (PBS with 2% 
DMSO) (n= 7) or vehicle (n= 7) from E10 to the day of delivery (E20/21), i.e. during the critical time 
windows when the majority of brain neurons are born. Hereafter the progeny of females that 
received 7,8-DHF will be called “treated mice” whereas the progeny of females that received the 
vehicle will be called “untreated mice”. On P2 the progeny of treated and untreated females 
received an intraperitoneal injection of BrdU (150 µg/g body weight) (Sigma Aldrich) in TrisHCl 50 
mM 2 hours before being killed, in order to label proliferating cells. The body weight was recorded 
prior to sacrifice. After sacrifice, the brain was excised and weighed. 
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Fig.9. Experimental protocol. Ts65Dn pregnant female received a daily subcutaneous injection of ether 7,8-DHF (5 
mg/kg) or vehicle from E10 to delivery. The littermates at P2 received an intraperitoneal injection of BrdU and were killed 
after 2 hours.  
 
 
 Males Females Total 
Eu+Veh 5 4 9 
Ts65Dn+Veh 7 2 9 
Eu+7,8-DHF 4 4 8 
Ts65Dn+7,8-DHF 3 8 11 
 
Table.4. Number of embryonically treated mice used in the study. 7,8-DHF, 7,8-dihydroxyflavone; Eu, Euploid; Veh, 
Vehicle. 
 
Histological procedures  
 
P2 animals were decapitated and the brain was removed. The rostral brain (forebrain plus 
mesencephalon) was separated from the hindbrain (cerebellum, pons and medulla), cut along the 
midline and fixed by immersion in Glyo-Fixx (Thermo Electron) for 24 h and then dehydrated 
through a series of ascending ethanol concentrations. Each hemisphere was embedded in paraffin, 
cut in series of 8-µm-thick coronal sections that were attached to polylysine coated slides. The right 
hemisphere was used for BrdU immunohistochemistry, the left hemisphere was used for Nissl-
staining. 
BrdU immunohistochemistry. One out of 20 sections (n=15-19 sections) from the rostral brain was 
incubated with a primary rat anti-BrdU antibody (diluted 1:200; Biorad) and a mouse monoclonal 
anti-NeuN (Neuronal-specific nuclear protein), a marker of mature neurons (diluted 1:250, 
Chemicon, Billerica, MA, USA). Detection was performed with a Cy3-conjugated anti rat secondary 
antibody for BrdU immunohistochemistry (diluted 1:200; Jackson Immunoresearch) and a FITC-
conjugated anti-mouse IgG (1:100; Sigma-Aldrich) for NeuN immunohistochemistry. 
Nissl-method. One out of 20 sections (n=15-19) from the rostral brain of P2 mice were stained with 




Number of BrdU-positive cells. BrdU-positive cells were sampled in the SVZ, DG, neocortex (CX), 
striatum (STR), thalamus (TH), and hypothalamus (HYP) of P2 mice. The brain coordinates (BC) 
reported below for these regions refer to the "Atlas of the developing mouse brain” (Paxinos et al., 
2007). Since cells that are going to populate the telencephalon arise from different regions of the 
VZ/SVZ (Brazel et al., 2003), we evaluated the effects of treatment in two different rostro-caudal 
regions of the SVZ. The region that stretches from the rostral horn of the lateral ventricle to the 
beginning of the hippocampal formation (BC: 2.19-3.15 mm) named here rostral SVZ (rSVZ) and the 
region that stretches from the beginning to the end of the hippocampal formation (BC: 3.27-4.84 
mm) named here caudal SVZ (cSVZ). In the neonatal DG, cells are scattered throughout the hilus, 
SGZ and granule cell layer, we evaluated the number of BrdU-positive cells in all these layers along 
the whole rostro-caudal extent of the hippocampal formation (BC: 3.27-4.84 mm). For simplicity, 
the layers in the DG where cells were counted will be called hereafter SGZ. In the CX, BrdU-positive 
cells were separately evaluated in the rostral cortex (rCX), namely the CX overlying the rSVZ (BC: 
2.19-3.15 mm) and in the caudal cortex (cCX), namely the portion of the CX overlying the cSVZ (BC: 
3.27-4.84 mm). In the STR cells were counted in sections that encroached the rSVZ (BC: 2.19-3.15 
mm). In the TH and HYP cells were counted in sections comprised between the BC 3.27-4.23 and 
the BC 2.67-3.87 mm, respectively.  
BrdU-positive cells were detected using a fluorescence microscope (Eclipse; objective: x 20, 0.5 NA). 
Quantification of BrdU-labeled nuclei was conducted in every 20th section. All BrdU-labeled cells 
located in the region of interest were counted using a modified unbiased stereology protocol that 
has previously been reported to successfully quantify BrdU labeling (Kempermann, 2002; Malberg, 
, 2000; Tozuka, 2005). The total number of BrdU-labeled cells per animal was determined and 
multiplied by 20 (the inverse of the section sampling fraction = 1/20) to obtain the total estimated 
number of cells per each region of interest.  
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Fig.10. Brain regions where proliferating cells were sampled. a-d: Examples of coronal sections from the brain of P2 
mice. Sampled region in the rostral cortex, rostral subventricular zone, striatum (a), caudal subventricular zone, dentate 
gyrus (b), thalamus, hypothalamus (c), caudal cortex, caudal SVZ (d). BrdU-positive cells (red) were counted in the areas 
enclosed by stippled lines or dots. Calibration bars = 500 µm. CA1, hippocampal field; CA3, hippocampal field; CX, cortex; 
cCX, caudal cortex; cSVZ; caudal subventricular zone; d, dorsal; DG, dentate gyrus; FI, fimbria; HYP, hypothalamus; l, 
lateral; LV, lateral ventricle; m, medial; rCX; rostral cortex; SVZ, subventricular zone; rSVZ, rostral subventricular zone; 
TH, thalamus; v, ventral. 
 
Stereology. Stereology was conducted in every 20th Nissl-stained section. The volume of the granule 
cell layer of the DG, pyramidal layer of field CA1, cell numerical density (De) and number of neurons 
in the DG and CA1 were estimated as previously described (Bianchi, 2010). Counting frames 
(disectors) with a side length of 15 µm and a height of 8 µm spaced in a 100 µm square grid 
(fractionator) were used. The De in layers II and VI of the cCX overlying hippocampal field CA1 was 
evaluated using counting frames with a side length of 15 µm (in layer II) and 20 µm (in layer VI) and 
a height of 8 µm spaced in a 100 µm square grid. In layer II cells were counted in the portion of the 
layer close to layer I, in layer VI cells were counted in the portion of the layer close to the subcortical 
plate. The thickness of the cCX overlying field CA1 was measured by tracing radial lines across the 




Fig.11. Example of the neocortex and hippocampal region where stereology was conducted. (a)  Nissl-stained coronal 
section encroaching the cCX and the hippocampal formation. (b) Higher magnification of the region enclosed in the 
rectangle in (a) showing the cortical layers (ordinal numbers). Red arrows indicate the regions where cells were counted 
in layer II, black arrows indicate the regions where cells where counted in were layer VI. Calibration in (a) = 500 µm. 
Calibrations in (b) = 50 µm. 7,8-DHF, 7,8-dihydroxyflavone; CA1, hippocampal field; CA3, hippocampal field; cCX, caudal 
cortex; d, dorsal; DG, dentate gyrus; Eu, euploid; FI, fimbria; IZ, intermediate zone; l, lateral; m, medial; SP, subplate; 
SVZ, subventricular zone; TH, thalamus; v, ventral; Veh, vehicle. 
 
All measurements were carried out by an experimenter blinded to the study code. 
The number of mice used for the analysis of BrdU-positive cells and stereology in the regions of 
interest is reported in Table 5. Note that the number of mice used for individual measurements may 




ROI rSVZ cSVZ DG rCX cCX STR TH HYP 
ME Tot Tot Tot Tot Tot Tot Tot Tot 
Eu+Veh 8 9 9 9 9 9 9 9 
Ts65Dn+Veh 7 7 6 7 6 7 7 7 
Eu+7,8-DHF 8 8 6 8 8 8 8 8 








cCX DG DG DG CA1 CA1 CA1 
ME De De Thick Vo De Tot Vo De Tot 
Eu+Veh 7 7 7 6 6 6 6 5 5 
Ts65Dn+Veh 6 7 8 6 5 5 6 5 5 
Eu+7,8-DHF 5 5 5 5 5 5 5 5 5 
Ts65Dn+7,8-DHF 6 8 8 8 8 8 8 5 5 
 
Table.5. Number of mice used for the evaluation of proliferation potency and stereology in the examined regions. 
The numbers in each column indicate the number of mice used for the measurements (ME), indicated in the 
corresponding row, in the different regions of interest (ROI), indicated in the corresponding row. Sections processed for 
BrdU immunohistochemistry were used to evaluate the total number of proliferating cells. Nissl-stained sections were 
used for stereology. 7,8-DHF, 7,8-dihydroxyflavone; CA1, hippocampal field; cCX, caudal cortex; cSVZ, caudal 
subventricular zone; De, cell density; DG, dentate gyrus; Eu, euploid; HYP, hypothalamus; L II, layer two; L VI, layer sixth; 
rCX, rostral cortex; rSVZ, rostral subventricular zone; STR, striatum; Thick, thickness; TH, thalamus; Tot, total cell number; 




Results are presented as mean ± standard error of the mean (SE). Data were analyzed with the IBM 
SPSS 22.0 software. Before running statistical analyses, we checked data distribution and 
homogeneity of variances for each variable using the Shapiro-Wilk test and Levene’s test, 
respectively. If the data were normally distributed and variance was homogeneous, statistical 
analysis was carried out using a two-way ANOVA with genotype (euploid, Ts65Dn) and treatment 
(vehicle, 7,8-DHF) as factors. Post hoc multiple comparisons were then carried out using Fisher’s 
least significant difference (LSD) test. If the data were not normally distributed and variance was 
heterogeneous, transformations were made to achieve normality. If the transformed data did not 
achieve normality, statistical analysis was carried out using the Kruskal-Wallis test followed by the 
Mann–Whitney U test. Based on the “Box plot” tool available in SPSS Descriptive Statistics, in each 
analysis we excluded the extremes, i.e., values that were larger than 3 times the IQ range [x ≥ Q3 + 
3 * (IQ); x ≤ Q1 – 3 * (IQ)]. The number of mice included in individual analyses is reported in the 







The list reports the abbreviations used in the Results and Discussion 
 
cCX  caudal cortex 
cSVZ  caudal subventricular zone  
CX  neocortex 
HYP  hypotalamus 
rSVZ  rostral subventricular zone 
rCX  rostral cortex  
SGZ  subgranular zone  
STR  striatum  
TH  thalamus 
RESULTS  
 
General results  
 
Effects of embryonic treatment with 7,8-DHF on abortion rate, perinatal death, and 
litter size. 
 
The Ts65Dn mouse is the most widely used mouse model of DS. However, this strain is fragile and 
difficult to maintain. Males are sterile and female are generally poor mothers. Moreover, although 
loss of both euploid and trisomic mice occurs during the latter stage of gestation and between birth 
and weaning, trisomic mice are lost disproportionately (Roper, 2006). In view of this reason we 
deemed it important to evaluate whether prenatal treatment with 7,8-DHF affects the abortion rate 
and the number of pups per litter. Ts65Dn female treated with 7,8-DHF during pregnancy did not 
exhibit higher abortion rate in comparison to the untreated counterpart (Table 6). 
 66 
 
Treatment   Abortion  
 n Mean  SE 
Vehicle 7 0.00 0.00 
7,8-DHF 7 0.14 0.14 
p  n.s.  
 
Table.6. Effects of embryonic treatment with 7,8-DHF on abortion rate. Pregnancy outcome for Ts65Dn females treated 
with vehicle (n=7) or 7,8-DHF (n=7) from gestational day 10 to delivery. The number of spontaneous abortions is 
expressed as the mean of total pregnancies of each group. Data are mean ± SE. n.s, not significant (Kruskall-Wallis test).  
 
The number of mice per litter and their survival rate was similar between treated and untreated 
mice (Table 7). 
 
Treatment   Litter size   Postnatal 
death 
 
 n Mean  SE Mean  SE 
Vehicle 7 5.50 0.74 4.08 4.08 
7,8-DHF 7 5.71 0.68 8.84 5.73  
p  n.s.  n.s.  
 
Table.7. Effects of embryonic treatment with 7,8-DHF on perinatal death and litter size. Litters of females treated with 
vehicle (n=7) or 7,8-DHF (n=7) from gestational day 10 to delivery. Litter size is expressed as mean of individual litters. 
Postnatal death is expressed as the mean of the percentage of deaths over numbers of births. Data are mean ± SE (two-
tailed t-test, for litter size; Kruskall-Wallis test for postnatal death).  
 
These results indicated that prenatal treatment with 7,8-DHF has no adverse effects on pregnancy 
and pups viability.   
 
Effect of embryonic treatment with 7,8-DHF on body and brain weight in Ts65Dn and 
euploid mice.  
 
To establish the global effect of prenatal treatment with 7,8-DHF we evaluated the body and brain 
weight of P2 mice. A two-way ANOVA on the body weight showed no genotype x treatment 
interaction, a main effect of genotype [F (1,33) = 11.089, p = 0.002] and no main effect of treatment. 
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A post hoc Fisher’s LSD test showed no difference in the body weight between untreated euploid 
and untreated Ts65Dn but that treated Ts65Dn mice had a reduced body weight in comparison with 
treated euploid mice. This finding is in line with the reduced body weight that characterizes the 
Ts65Dn mouse model (Guidi, 2014; Roper, 2006). Treatment with 7,8-DHF had no effect on body 
weight both in euploid and Ts65Dn mice (Table 8).  
 
 n Mean SE  n Mean SE  
        p 
Eu+ Veh 9 1.87 ± 0.09 Eu+7,8-DHF 8 2.02 ±0.07 n.s. 
Ts65Dn+Veh 9 1.68 ± 0.16 Ts65Dn+7,8-DHF 11 1.53 ±0.06 n.s 
p n.s     <0.01   
 
Table.8. Effects of embryonic treatment with 7,8-DHF on body weight. Body weight of P2 mice used in the current 
study. The mice received either vehicle (Veh) or 7,8-DHF during the embryonic period E10-E20/21. The p value in the row 
below the two genotypes refers to the comparison between untreated euploid (Eu+Veh) and Ts65Dn (Ts65Dn+Veh) mice 
and treated euploid (Eu+7,8-DHF) and (Ts65Dn+7,8DHF) mice. The p value in the column on the right refers to the 
comparison between untreated and treated mice of the same genotype. Data are mean ± SE (Fisher’s LSD test after two-
way ANOVA). 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; n, number of mice; n.s, not significant; SE, standard error; Veh, 
vehicle. 
 
A two-way ANOVA on the brain weight showed no genotype x treatment interaction, no main effect 
of genotype, and no main effect of treatment. In absolute terms the brain weight of Ts65Dn mice 
was smaller in comparison with their untreated counterparts (see Table 8) which is in agreement 
with data from the literature (Belichenko 2004; Guidi, 2014; Stagni, 2017). Taken together, these 
results suggest that treatment with 7,8-DHF do not negatively affects body growth and brain 
development.  
 
 n Mean SE  n Mean SE  
        p 
Eu+ Veh 9 0.12 ± 0.01 Eu+7,8-DHF 8 0.12 0.01 n.s. 
Ts65Dn+Veh 9 0.11 ± 0.01 Ts65Dn+7,8-DHF 11 0.10 0.01 n.s 
p n.s     n.s.   
 
Table.9. Effects of embryonic treatment with 7,8-DHF on brain weight. Brain weight of P2 mice used in the current 
study. The mice received either vehicle (Veh) or 7,8-DHF during the embryonic period E10-E20/21. The p value in the row 
below the two genotypes refers to the comparison between untreated euploid (Eu+Veh) and Ts65Dn (Ts65Dn+Veh) mice 
and treated euploid (Eu+7,8-DHF) and (Ts65Dn+7,8DHF) mice. The p value in the column on the right refers to the 
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comparison between untreated and treated mice of the same genotype. Data are mean ± SE (Fisher’s LSD test after two-
way ANOVA). 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; n, number of mice; n.s, not significant; SE, standard error; Veh, 
vehicle. 
 
Widespread neurogenesis in P2 mice  
 
In the mouse brain 90% of the cell population of the SVZ is dividing at E16, whereas the majority of 
the cells in the VZ are leaving the cell cycle. Neurons that are going to populate the neocortex, the 
hippocampus, the striatum, thalamus and hypothalamus are mainly born between the embryonic 
period E10-E19 (Brazel, 2003; Nery, 2002). Indeed, with the exception of DG and cerebellum (the 
latter not under investigation in this study) neurogenesis is mainly a prenatal event. In the DG, unlike 
other brain regions, neurogenesis starts around E10 but most of the granule neurons (80%) are 
generated in the postnatal SGZ (Altman,1975; Brazel, 2003). In P2 mice we observed numerous 
neural precursor cells in the SVZ and SGZ. In addition, proliferating cells were also scattered 
throughout the neocortex, striatum, thalamus, and hypothalamus. In order to establish the possible 
efficacy of a prenatal treatment with 7,8-DHF on the proliferation potency of neural precursor cells 
and their progeny, in embryonically treated P2 mice we evaluated the number of BrdU-positive cells 
in the rostral and caudal part of the SVZ, rostral and caudal part of the neocortex, SGZ, striatum, 
thalamus and hypothalamus. 
 
Effect of embryonic treatment with 7,8-DHF on the proliferation potency in the rSVZ 
of Ts65Dn and euploid mice. 
  
Although cells arising from the rSVZ and cSVZ can populate the entire cortical mantle, it appears 
that cells arising from the rSVZ preferentially distribute to the rCX and cells arising from the cSVZ 
preferentially distribute to the cCX (Brazel, 2003). For this reason, we evaluated the effect of 
embryonic treatment in these two different rostro-caudal regions of the SVZ separately.  
A two-way ANOVA on the number of BrdU-positive cells in the rSVZ showed a genotype x treatment 
interaction [F (1,27) = 5.109, p = 0.032], a main effect of genotype [F (1,27) = 17.750, p = 0.001], and 
no main effect of treatment. A post hoc Fisher’s LSD test showed that untreated Ts65Dn mice had a 
reduced proliferation potency (-34%) compared with untreated euploid mice. Ts65Dn mice treated 
with 7,8-DHF have an increased (+25%) number of BrdU-positive cells in comparison with their 
untreated counterparts. Although Ts65Dn mice treated with 7,8-DHF showed a significant 
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increment in the number of BrdU-positive cells, this effect was not a restoration because treated 
Ts65Dn mice still had fewer BrdU-positive cells in comparison with euploid mice. In euploid mice 
treatment had no effect on the number of BrdU-positive cells in the rSVZ. 
 
 
df F Sign. 
genotype 1 17,750 ,000 
treatment 1 ,910 ,349 
genotype x  
treatment 




Table.10. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the rSVZ of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU-positive cells 
 p 







Table.11. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 






Fig.12. Effect of embryonic treatment with 7,8-DHF on neural precursor proliferation in the rostral subventricular 
zone of P2 Ts65Dn and euploid mice. A) Examples of sections immunostained for BrdU and NeuN from the rSVZ of an 
animal of each experimental group. Calibration=200µm. B) Total number of BrdU positive cells in the rSVZ of untreated 
euploid (n=8) and Ts65Dn (n=7) mice and euploid (n=8) and Ts65Dn (n=9) mice treated with 7,8-DHF. Values (mean ± 







































Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 7,8-DHF, 
7,8-dihydroxyflavone; Eu, euploid; LV, lateral ventricle; rSVZ, rostral subventricular zone; Veh, vehicle. 
 
Effect of embryonic treatment with 7,8-DHF on the proliferation potency in the cSVZ 
of Ts65Dn and euploid mice.  
 
A two-way ANOVA on the number of BrdU-positive cells in the cSVZ showed no genotype x 
treatment interaction, a main effect of genotype [F (1,30) = 17.181, p < 0.001], and a main effect of 
treatment [F(1,30) =  15.286, p < 0.001]. A post hoc Fisher’s LSD test showed that untreated Ts65Dn 
mice had a reduced number of proliferating cells (-32%) in comparison with untreated euploid mice. 
In Ts65Dn mice treated with 7,8-DHF the number of BrdU-positive cells underwent an increase 
(+45%) in comparison with their untreated counterparts. A comparison of untreated euploid mice 
and Ts65Dn mice treated with 7,8-DHF showed no difference between groups indicating that 
treatment had restored the number of proliferating cells in the cSVZ. Treated euploid mice showed 










Table.12. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the cSVZ of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU positive cells 
 p 







Table.13. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 




df F Sign. 
genotype 1 17,181 ,000 
treatment 1 15,286 ,000 
genotype x  
treatment 





Fig.13. Effect of embryonic treatment with 7,8-DHF on neural precursor proliferation in the caudal subventricular 
zone of P2 Ts65Dn and euploid mice. A) Examples of sections immunostained for BrdU and NeuN from the cSVZ of an 
animal of each experimental group. Calibration=100µm. B) Total number of BrdU positive cells in the cSVZ of untreated 
euploid (n=9) and Ts65Dn(n=7) mice and euploid (n=8) and Ts65Dn (n=10) mice treated with 7,8-DHF. Values (mean ± 
SE) represent totals for one hemisphere.  ** p < 0.01; *** p < 0.001 (Fisher’s LSD test after two-way ANOVA). Black 
asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. White asterisks 
in the black bar indicate a difference between treated Ts65Dn mice and treated euploid mice. 7,8-DHF, 7,8-





































Effect of embryonic treatment with 7,8-DHF on the proliferation potency in the dentate 
gyrus of Ts65Dn and euploid mice.  
 
While in the adult brain proliferating cells of the dentate gyrus are located in the SGZ, during the 
neonatal period proliferating cells are scattered throughout all layers of the DG. For this reason, we 
evaluated the number of proliferating cells located in the hilus, SGZ, and granule cell layer, along 
the whole rostro-caudal extent of the hippocampus.  
A two-way ANOVA on the total number of BrdU-positive cells in the DG showed no genotype x 
treatment interaction, a main effect of genotype [F (1,28) = 13.068, p = 0.001], and no main effect 
of treatment. A post hoc Fisher’s LSD test showed that in untreated Ts65Dn mice the number of 
proliferating cells was lower (-25%) compared with untreated euploid mice. The number of 
proliferating cells in treated Ts65Dn mice underwent an increase (+21%) and became similar to that 
of untreated euploid mice. Treatment showed no effect on the number of proliferating cells in the 
DG of euploid mice. 
 
 
df F Sign. 
genotype 1 3,017 ,093 
treatment 1 13,068 ,001 
genotype x  
treatment 




Table.14. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the DG of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU positive cells 
 p 







Table.15. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 





 Fig.14. Effect of embryonic treatment with 7,8-DHF on neural precursor proliferation in dentate gyrus of P2 Ts65Dn 
and euploid mice. A) Examples of sections immunostained for BrdU and NeuN from the DG of an animal of each 
experimental group. Calibration=100µm. B. Total number of BrdU positive cells in the hilus+granule cell layer of the DG 
of untreated euploid (n=9) and Ts65Dn(n=6) mice and euploid (n=6) and Ts65Dn (n=11) mice treated with 7,8-DHF. 
Values (mean ± SE) represent totals for one hemisphere. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher’s LSD test after 
two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated 






































Effect of embryonic treatment with 7,8-DHF on the proliferation potency in the rostral 
neocortex of Ts65Dn and euploid mice.  
 
We separately evaluated cells located in the cortex overlying the rSVZ and cells located in the cortex 
overlying the cSVZ. A two-way ANOVA on the total number of BrdU-positive cells in the rostral 
neocortex showed no genotype x treatment interaction, a main effect of genotype [F (1,31) = 
12.667, p = 0.001] and a main effect of treatment [F (1,31) = 8.315, p = 0.007]. A post hoc Fisher’s 
LSD test showed that the number of proliferating cells in untreated Ts65Dn mice was lower (-39%) 
in comparison with untreated euploid mice. In treated Ts65Dn mice the number of proliferating 
cells underwent an increase (+45%) in comparison with their untreated counterparts and became 
similar to that of untreated euploid mice. In euploid mice prenatal treatment had no effect on the 
number of BrdU-positive cells.  
 
  df F Sign. 
genotype 1 12,667 ,001 
treatment 1 8,315 ,007 
genotype x  
treatment 




Table.16. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the rCX of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU-positive cells 
 p 







Table.17. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 





 Fig.15. Effect of embryonic treatment with 7,8-DHF on proliferating cells in the rostral neocortex of P2 Ts65Dn and 
euploid mice. A) Examples of sections immunostained for BrdU and NeuN from the rCX of an animal from each 
experimental group. Calibration bar = 50 µm. B) Total number of BrdU-positive cells in the rCX of untreated euploid (n= 
9) and Ts65Dn (n=7) mice and euploid (n=8) and Ts65Dn (n=9) mice treated with 7,8-DHF. Values (mean ±  SE) in 
represent totals for one hemisphere. * p < 0.05; ** p<0.01; *** p < 0.001 (Fisher’s LSD test after two-way ANOVA). Black 
asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 7,8-DHF, 7,8-





























Effect of embryonic treatment with 7,8-DHF on the proliferation potency in the caudal 
neocortex of Ts65Dn and euploid mice.  
 
 A two-way ANOVA on the total number of BrdU-positive cells in the caudal neocortex showed no 
genotype x treatment interaction, a main effect of genotype [F (1,29) = 20.417, p < 0.001] and no 
main effect of treatment. A post hoc Fisher’s LSD test showed that untreated Ts65Dn mice displayed 
fewer proliferating cells (-45%) in comparison with untreated euploid mice. In treated Ts65Dn mice 
the number of BrdU-positive cells did not increase in comparison with their untreated counterparts.  
 
 
df F Sign. 
genotype 1 20,417 ,000 
treatment 1 3,454 ,073 
genotype x  
treatment 




Table.18. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the cCX of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU-positive cells 
 p 







Table.19. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 







Fig.16. Effect of embryonic treatment with 7,8-DHF on proliferating cells in the caudal neocortex of P2 Ts65Dn and 
euploid mice. Total number of BrdU-positive cells in the cCX of untreated euploid (n= 9) and Ts65Dn (n=6) mice and 
euploid (n=8) and Ts65Dn (n=11) mice treated with 7,8-DHF. Values (mean ± SE) represent totals for one hemisphere. * 
p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher’s LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a 
difference between untreated Ts65Dn mice and treated euploid mice. White asterisks in the black bar indicate a 
difference between treated Ts65Dn mice and treated euploid mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, 
vehicle. 
 
Effect of embryonic treatment with 7,8-DHF on the proliferation potency in the 
striatum of Ts65Dn and euploid mice  
Part of the cells arising from the LGE during the embryonic period migrate to constitute the striatum. 
A two-way ANOVA on the total number of BrdU-positive cells in the striatum showed no genotype 
x treatment interaction, a main effect of genotype [F (1,30) = 16.564, p < 0.001], and a main effect 
of treatment [F (1,30) = 8.493, p = 0.007]. A post hoc Fisher’s LSD test showed that untreated Ts65Dn 
mice had fewer proliferating cells (-36%) in comparison with untreated euploid mice. Treatment 
increased the number of BrdU-positive cells (+40%) in Ts65Dn mice in comparison with their 
untreated counterparts and, although this effect was only marginally significant, the number of 
BrdU-positive cells became similar to that of untreated euploid mice. Euploid mice showed an 




























df F Sign. 
Genotype 1 16,564 ,000 
treatment 1 8,493 ,007 
genotype x  
treatment 




Table.20. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the STR of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Total number of BrdU-positive cells 
 p 







Table.21. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 





Fig.17. Effect of embryonic treatment with 7,8-DHF on proliferating cells in the striatum of P2 Ts65Dn and euploid 
mice.  A) Examples of sections immunostained for BrdU and NeuN from the STR of an animal from each experimental 
group. Calibration = 50 µm. B) Total number of BrdU-positive cells in the STR of untreated euploid (n= 9) and Ts65Dn 
(n=7) mice and euploid (n=8) and Ts65Dn (n=10) mice treated with 7,8-DHF. Values (mean ± SE) represent totals for one 
hemisphere. (*) p <0.06; * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher’s LSD test after two-way ANOVA). Black asterisks 
in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. White asterisks in the 
black bar indicate a difference between treated Ts65Dn mice and treated euploid mice. 7,8-DHF, 7,8-dihydroxyflavone; 



























Effect of embryonic treatment with 7,8 DHF on the proliferation potency in the 
thalamus of Ts65Dn and euploid mice  
Cells populating the thalamus derive from the MGE and LGE (Brazel, 2003). A two-way ANOVA on 
the number of BrdU-positive cells in the thalamus showed no genotype x treatment interaction, a 
main effect of genotype [F (1,20) = 4.735, p < 0.038], and no main effect of treatment. A post hoc 
Fisher’s LSD test showed that untreated Ts65Dn mice had a reduced number of proliferating cells (-
40%) in comparison with untreated euploid mice. Treatment did not significantly increase the 
number of proliferating cells in comparison with their untreated counterparts, although in absolute 
terms the number of proliferating cells became larger in treated (16,179 ±1582) in comparison with 
untreated (11,953 ±1561) Ts65Dn mice and was statistically similar to that of untreated euploid 
mice. No effect of treatment was found in the thalamus of euploid mice. 
 
df F Sign. 
Genotype 1 4,735 ,038 
treatment 1 ,169 ,684 
genotype x 
treatment 




Table.22. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the TH of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU positive cells 
 p 







Table.23. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 





Fig.18. Effect of embryonic treatment with 7,8-DHF on proliferating cells in the thalamus of P2 Ts65Dn and euploid 
mice. A) Examples of sections immunostained for BrdU and NeuN from the TH of an animal from each experimental 
group. Calibration bar= 50 µm. B) Total number of BrdU-positive cells in the TH of untreated euploid (n=9) and Ts65Dn 
(n=7) mice and euploid (n=8) and Ts65Dn (n=9) mice treated with 7,8-DHF. Values (mean ± SE) represent totals for one 
hemisphere. * p < 0.05 (Fisher’s LSD test after two-way ANOVA). Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, 



























Effect of embryonic treatment with 7,8 DHF on the proliferation potency in the 
hypothalamus of Ts65Dn and euploid mice  
A two-way ANOVA on the number of BrdU-positive cells in the hypothalamus showed no genotype 
x treatment interaction, a main effect of genotype [F(1,20) = 7.928, p < 0.009], and no main effect 
of treatment. A post hoc Fisher’s LSD test showed that in untreated Ts65Dn mice the number of 
proliferating cells was lower (-45%) in comparison with untreated euploid mice. Treatment did not 
increase the number of proliferating cells in Ts65Dn mice that remained lower (-35%) in comparison 
with untreated euploid mice (Fig. 18).  
 
df F Sign. 
genotype 1 7,928 ,009 
treatment 1 ,002 ,962 
genotype x  
treatment 
1 ,738 ,397 
Error 30     
 
Table.24. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of BrdU positive 
cells in the HYP of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Number of BrdU positive cells 
 p 







Table.25. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 
number of BrdU positive cells in the hypothalamus of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, 




Fig.18. Effect of embryonic treatment with 7,8-DHF on proliferating cells in the hypothalamus of P2 Ts65Dn and 
euploid mice. Total number of BrdU-positive cells in the HYP of untreated euploid (n= 9) and Ts65Dn (n=7) mice and 
euploid (n=8) and Ts65Dn (n=9) mice treated with 7,8-DHF. Values (mean ± SE) represent totals for one hemisphere. * p 
< 0.05 (Fisher’s LSD test after two-way ANOVA). Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
 
Effect of embryonic treatment with 7,8-DHF on cellularity in Ts65Dn and euploid mice  
Considering the positive effects of prenatal treatment with 7,8-DHF on the proliferation potency in 
the SVZ and SGZ of Ts65Dn mice we wanted to investigate whether this effect translated into an 
increase in cell number. To this purpose, we evaluated the number of cells in the caudal neocortex, 
granule cell layer of the DG and pyramidal layer of hippocampal field CA1.  
Effect of embryonic treatment with 7,8-DHF on cortical thickness in the caudal 
neocortex of Ts65Dn and euploid mice  
A two-way ANOVA on the thickness of the caudal neocortex showed no genotype x treatment 
interaction, no main effect of genotype, and a main effect of treatment [F (1,24) = 6.293, p = 0.019]. 
A post hoc Fisher’s LSD test showed no difference in cortical thickness between untreated Ts65Dn 
and untreated euploid mice, although in absolute terms the cortical thickness of untreated euploid 
mice was larger in comparison with that of Ts65Dn mice. Untreated Ts65Dn mice had a reduced 
cortical thickness in comparison with treated euploid mice. Treatment had no effect on the cortical 
























df F Sign. 
genotype 1 2,842 ,105 
treatment 1 6,293 ,019 
genotype x  
treatment 




Table.26. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the thickness of the cCx of 
euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Thickness  
 p 







Table.27. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 
thickness of the cCx of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
 
Fig.20. Effect of embryonic treatment with 7,8-DHF on cortical thickness in P2 Ts65Dn and euploid mice. Cortical 
thickness (layers II-VI) in untreated euploid (n=7) and Ts65Dn (n=6 for layer II; n=7 for layer VI;) mice and euploid (n=5) 
and Ts65Dn (n=6 for layer II; n=8 for layer VI) mice treated with 7,8-DHF. p < 0.05; ** (Fisher’s LSD test after two-way 
ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 
7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
Effect of embryonic treatment with 7,8-DHF on cell density in the caudal neocortex of 
Ts65Dn and euploid mice  
The neocortex develops in an inside-outside fashion, with older neurons located in the deep cortical 





















treatment had an effect on cellularity in layer II and layer VI because these layers contain neurons 
with a different date of birth. Consequently, progenitors of neurons of layer II were exposed to 
treatment for a longer time, while progenitors of neurons of layer VI were exposed to treatment for 
a shorter time. A two-way ANOVA on cell density in layer II showed a genotype x treatment 
interaction [F(1,20)  = 14.119, p = 0.01], a main effect of genotype [F(1,20) = 21.563, p < 0.01], and 
a main effect of treatment [F(1,20)  = 5.575, p = 0.028]. A post hoc Fisher’s LSD test showed that cell 
density was lower (-10%) in untreated Ts65Dn mice in comparison with untreated euploid mice. 
Treatment increased cell density (+8%) in Ts65Dn mice to a value similar to that of untreated euploid 
mice. In euploid mice treatment had no effect on cell density in layer II. Although we could not 
statistically compare data of layer VI cell density, because the Kruskal-Wallis test did not show a 
significant effect, the graph in Figure 21 shows that different groups had similar value  
 
gl F Sign. 
genotype 1 21,563 ,000 
treatment 1 5,575 ,028 
genotype x  
treatment 




Table.28. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on cell density of cortical layer II 








Table.29. The table reports the results of the Kruskal-Wallis test on the effect of 7,8-DHF on cell density of cortical layer 
IV of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Cell density  
 Layer II 
 p 







Table.30. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the cell 
density of the cCx of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
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Fig. 21. Effect of embryonic treatment with 7,8-DHF on cell density in P2 Ts65Dn and euploid mice. Cell number (cells 
per mm3) in layer II and layer VI in untreated euploid (n=7) and Ts65Dn (n=6 for layer II; n=7 for layer VI;) mice and 
euploid (n=5) and Ts65Dn (n=6 for layer II; n=8 for layer VI) mice treated with 7,8-DHF. ; *** p < 0.001 (Fisher’s LSD test 
after two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated 
euploid mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
Effect of embryonic treatment with 7,8-DHF on the stereology of the dentate gyrus of 
the hippocampus of Ts65Dn and euploid mice  
A two-way ANOVA on the volume of the DG showed no genotype x treatment interaction, a main 
effect of genotype [F (1,21) = 8.974, p = 0.010], and no main effect of treatment. A post hoc Fisher’s 
LSD test showed that the volume of the granule cell layer of untreated Ts65Dn mice was reduced in 
comparison with that of untreated euploid mice. The volume of the granule cell layer of treated 
Ts65Dn mice became statistically similar to that of untreated euploid mice, although in absolute 
terms its size was smaller than that of euploid mice. The Kruskal-Wallis test showed no significant 
effect on granule cell density. A two-way ANOVA on total number of granule cells showed no 
genotype x treatment interaction, a main effect of genotype [F(1,20) = 18.973, p < 0.001], and no 
main effect of treatment. A post hoc Fisher’s LSD test showed that in untreated Ts65Dn mice the 
number of granule cells was reduced in comparison with that of untreated euploid mice and that 
treatment did not restore total granule cell number that remained lower in comparison with 
untreated euploid mice.  
 
df F Sign. 
genotype 1 8,974 ,007 
treatment 1 1,147 ,296 
genotype x  
treatment 





























Table.31. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the volume of the DG of euploid 
and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Volume  
 p 







Table.32. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 






Table.33. The table reports the results of the Kruskal-Wallis test on the effect of 7,8-DHF on cell density of the granule 
cell layer of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
  
Df F Sign. 
genotype 1 18,973 ,000 
treatment 1 2,938 ,102 
genotype x  
treatment 




Table.34. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the total number of granule 
cells of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 Total number of granule cells 
 p 








Table.35. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 
total number of granule cells of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
 
Fig.22. Effect of embryonic treatment with 7,8-DHF on the stereology of the dentate gyrus in P2 Ts65Dn and euploid 
mice. Volume of the granule cell layer, density of granule cells (number per mm3) and total number of granule cells of 
the DG in untreated euploid (n= 6) and Ts65Dn (n=6) mice and euploid (n=5) and Ts65Dn (n=8) mice treated with 7,8-
DHF. Values (mean ± SE) refer to one hemisphere. (*) p < 0.06; * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher’s LSD test 
after two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated 
euploid mice. White asterisks in the black bar indicate a difference between treated Ts65Dn mice and treated euploid 
mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; DG, dentate gyrus; Eu, euploid; Veh, vehicle. 
 
Effect of embryonic treatment with 7,8-DHF on the stereology of the hippocampus of 
Ts65Dn and euploid mice  
A two-way ANOVA on the volume of the pyramidal layer of field CA1 showed no genotype x 
treatment interaction, a main effect of genotype [F(1,21) = 5.447, p = 0.030], and no main effect of 
treatment. A post hoc Fisher’s LSD test showed no difference between untreated Ts65Dn and 
euploid mice in the volume of the pyramidal layer and no effect of treatment. A two-way ANOVA 
on the density of pyramidal neurons showed a genotype x treatment interaction [F(1,20) = 6.360, p 
= 0.020], and no main effect of genotype and of treatment. A post hoc Fisher’s LSD test showed that 
untreated Ts65Dn mice had a reduced cell density in comparison with untreated euploid mice and 
that treatment increased cell density to a value similar to that of untreated euploid mice. A two-
way ANOVA on the number of pyramidal neurons showed no genotype x treatment interaction, a 
main effect of genotype [F(1,20) = 7.905, p = 0.011], and no main effect of treatment. A post hoc 
Fisher’s LSD test showed that untreated Ts65Dn mice had a reduced number of pyramidal neurons 
in comparison with untreated euploid mice. Although in Ts65Dn mice treatment did not significantly 





















































in absolute terms the number of pyramidal neurons became larger in treated (169,341±16,535) in 
comparison with untreated (149,690±19,064) mice and was statistically similar to that of untreated 
euploid mice.  
 
df F Sign. 
genotype 1 5,447 ,030 
treatment 1 ,020 ,888 
genotype x  
treatment 




Table.36. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on volume of the pyramidal layer 











Table.37. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on volume 
of the pyramidal layer of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
  
Df F Sign. 
Genotype 1 ,526 ,477 
treatment 1 1,252 ,276 
genotype x  
treatment 




Table.38. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on cell density in CA1 of euploid 
and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 
 CA1 cell density 
 p 








Table.39. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on cell 
density in CA1 of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
  
df F Sign. 
genotype 1 7,905 ,011 
treatment 1 ,165 ,689 
genotype x  
treatment 




Table.40. The table reports the results of the two-way ANOVA on the effect of 7,8-DHF on the number of pyramidal 
neurons of euploid and Ts65Dn mice. df, degree of freedom; sign, significance. 
 
 
 Number of pyramidal neurons 
 p 







Table.22. The table reports the p value of the Fisher’s LSD test after two-way ANOVA on the effect of 7,8-DHF on the 
number of pyramidal neurons of euploid and Ts65Dn mice. 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
 
Fig.23. Effect of embryonic treatment with 7,8-DHF on the stereology of the hippocampal field CA1 in P2 Ts65Dn and 
euploid mice. Volume of the pyramidal layer, density of pyramidal neurons (number per mm3) and total number of 
pyramidal neurons of field CA1 in untreated euploid (n= 6) and Ts65Dn (n=6) mice and euploid (n=5) and Ts65Dn (n=8) 
mice treated with 7,8-DHF. Values (mean ± SE) refer to one hemisphere. * p < 0.05; (Fisher’s LSD test after two-way 
ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 



















































In this study, consistently with previous evidence (Guidi, 2014), we observed a reduced proliferation 
potency in all the examined forebrain regions of Ts65Dn mice aged two days (P2). Prenatal 
treatment with 7,8-DHF was able to increase the number of proliferating cells in the SVZ of the 
Ts65Dn mice both in the rostral and caudal part. However, the magnitude of the effect was different 
between the two regions of the SVZ. While in the caudal part the number of proliferating cells in 
treated Ts65Dn mice became similar to that of untreated euploid mice, in the rostral part the 
number of proliferating cells in treated Ts65Dn mice remained lower in comparison with untreated 
euploid mice. In the SGZ of Ts65Dn mice treatment increased the pool of proliferating cells to a 
number similar to that of untreated euploid mice. In the rCX, STR and TH treatment enhanced the 
number of proliferating cells to a number statistically similar to that of untreated euploid mice 
although, in absolute terms, their number did not reach the value of euploid mice. At variance with 
the other examined regions the number of proliferating cells in the cCx and HYP of treated Ts65Dn 
mice was not increased by treatment. The embryonic VZ/SVZ of the lateral ventricle are the 
neurogenic niches from which the progenitors of neurons and glia cells that will constitute the 
telencephalon arise. The finding that in the SVZ of Ts65Dn mice treatment increased the number of 
proliferating cells indicates that 7,8-DHF positively enhances the proliferative potency of progenitor 
cells located in the SVZ. Considering that neurogenesis is mainly a prenatal event this suggests a 
positive effect of 7,8-DHF on the production of telencephalic neurons (and glia). 
The production of neurons and glia occurs at discrete time points during fetal brain development. 
Gliogenesis follows neurogenesis and persists long after neurogenesis has ceased. During the early 
postnatal period, the SVZ of the lateral ventricle gives origin to glial cells, initially astrocytes and 
then oligodendrocytes, destined to the cortex and striatum (Brazel, 2003; Miller, 2007). Therefore, 
the proliferating cells found in the CX and STR of P2 mice are cells (most likely glioblasts) derived 
from the SVZ that have retained proliferative capacity during their migration. The low number of 
actively dividing cells found in CX and STR of untreated Ts65Dn mice is in agreement with the 
reduced proliferation potency observed in the SVZ of untreated Ts65Dn mice. The increase in the 
number of proliferating cells in the CX and STR of Ts65Dn mice after embryonic treatment with 7,8-
DHF is consistent with the increase induced by treatment in the number of progenitors in the SVZ. 
In the cCX, at variance with rCX, treatment did not increase the number of proliferating cells. The 
molecular processes regulating astrocyte and oligodendrocyte precursor migration in DS remain 
poorly defined. However, the migration of cells from germinative zones not only depends on the 
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proliferation potency of the progenitor cells but is also under the control of environmental 
attractive/repulsive chemical signals (Brazel, 2003). The lack of an increase in the number of 
glioblasts in the cCX may be explained by lack of signals favoring cells migration.  
Cells in the SGZ are the progenitors of neurons and astrocytes forming the hippocampal DG. The 
reduced number of proliferating cells found in the SGZ of untreated Ts65Dn mice indicates that the 
formation of the DG is impaired from the earliest phases of development. The finding that prenatal 
administration of 7,8-DHF was able to completely restore the number of the progenitors of future 
granule cells and astrocytes in the SGZ of Ts65Dn mice indicates that those progenitors are sensitive 
to the effect of 7,8-DHF not only during neonatal period, as previously demonstrated (Stagni, , 
2017), but also during embryonic stages.  
The number of proliferating cells was also reduced in the thalamic and hypothalamic regions of 
Ts65Dn mice. Most of the neurons forming the thalamus and hypothalamus are born during the 
period E11-E19, in the time window of our treatment. The progenitors of these cells arise from the 
VZ/SVZ laying the III ventricles (Wang, 2011). The reduced proliferation potency observed in P2 
untreated Ts65Dn mice suggests that this reduction may be due to an impaired proliferation in the 
VZ/SVZ surrounding the III ventricle. This is consistent with the finding that aged people with DS 
have a reduction in the number of neuronal and glial cells in thalamic nuclei (Karlsen, 2014; Perry, 
2019). Although this reduction may be part of a neurodegenerative process, it is also conceivable 
that alteration of neurogenesis during early brain development may be a determinant of the 
reduced number of thalamic neurons. We found that prenatal treatment with 7,8 DHF was able to 
increase the number of proliferating cells in the thalamus but not in the hypothalamus of Ts65Dn 
mice. This suggests that prenatal treatment with 7,8-DHF exerts a positive effect on the proliferation 
of diencephalic neural progenitors, although this effect is limited to the progenitors of cells destined 
to the thalamus.  
 
Taken together these results demonstrate that early treatment with the natural flavonoid 7,8-DHF 
promotes a widespread pro-proliferative effect in the forebrain of the Ts65Dn mice. The magnitude 
of this pro-proliferative effects was different according to the brain region. 7,8-DHF specifically 
binds the TrkB receptor mimicking the action of the BDNF (Jang, 2010). Conflicting evidence exists 
concerning the pro-proliferative effect of the BDNF/TrkB system (Foltran, 2016; Vilar, 2016). Our 
previous study suggests that 7,8-DHF may influence proliferation in a non-cell autonomous manner 
(Stagni, 2017). The environment of the neurogenic niche and/or of the final destination of migrating 
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neuroblasts/glioblasts may explain the differences in the strength and distribution of the pro-
proliferative effect of 7,8-DHF observed here.  
 
P2 Ts65Dn mice displayed a reduced cell density in cortical layer II, but the number of cells in layer 
VI is similar to euploid mice, which is partially in agreement with our previous findings (Guidi, 2014). 
Embryonic treatment with 7,8-DHF in Ts65Dn mice was able to restore the number of cells of layer 
II and had no effect in layer VI. The restoration of cell density in layer II in treated Ts65Dn mice is 
coherent with the pro-proliferative effects of 7,8-DHF in the SVZ. Corticogenesis follow an inside-
outside pattern, earlier born neurons settle into the deeper layers while later born neurons migrate 
past them and colonize more superficial layers. Projection neurons of the deeper layers arise from 
the VZ, while projection neurons of the outer layers arise from the SVZ. Corticogenesis in mice 
begins approximately on E10 (Brazel, 2003), at the time we initiated the embryonic treatment. Thus, 
the progenitors of layer II neurons had been exposed to treatment for a longer period in comparison 
with the progenitor giving origin to layer VI neurons. The necessity of a relatively long exposure to 
7,8-DHF for the improvement of cell proliferation may explain the positive effect exerted by 7,8-
DHF on cellularity of layer II but not of layer VI.  
Since the hippocampus is a brain region seriously damaged in DS and exerts a critical role in learning 
and memory, we were interested in establishing whether prenatal treatment with 7,8-DHF was able 
to improve hippocampal development. Consistently with our previous study (Guidi, 2014), we found 
a reduced number of neurons in the DG and hippocampal field CA1 of P2 Ts65Dn mice. Prenatal 
treatment did not increase total cell number in the DG of Ts65Dn mice although it was able to 
attenuate the difference in comparison with euploid mice. Thus, although prenatal treatment with 
7,8-DHF was able to restore the number of the granule cell progenitors in the SGZ, its effect was not 
sufficient to restore the number of granule neurons. In the hippocampus, treatment restored cell 
density in field CA1 of Ts65Dn mice. The total number of pyramidal neurons, however, did not reach 
the value of untreated euploid mice.  
 
Taken together these results show that prenatal treatment with 7,8-DHF enhances cortical 
cellularity in Ts65Dn mice, but it has moderate effects on the hippocampal formation.  
From the comparison of the effects of embryonic treatment with 7,8-DHF found here and the effects 
of prenatal administration of fluoxetine observed in our previous study (Guidi, 2014) it clearly 
emerges that the effect of fluoxetine on brain development is remarkably more prominent in 
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comparison with 7,8-DHF. Prenatal treatment with fluoxetine restored the number of proliferating 
cells in the rostral and caudal SVZ, SGZ, rostral and caudal neocortex, striatum, thalamus and 
hypothalamus in addition to other regions not examined here. Furthermore, fluoxetine was able to 
restore cell density in all cortical layers, DG and hippocampus. While the beneficial effects of 7,8-
DHF disappear one month after treatment cessation (Giacomini, 2019), the effect of fluoxetine are 
retained after treatment cessation and translate into restoration of cognitive performance in 
adulthood (Guidi, 2014; Stagni, 2015). Taken together, these observations suggest that a prenatal 
treatment with fluoxetine could be a better choice than 7,8-DHF in order to restore the 
development of the trisomic brain. However, the use of fluoxetine during pregnancy may pose some 
caveats due to possible serious side effects, while 7,8-DHF in view of its chemical nature is 
potentially usable during gestation. Thus, despite its milder effects the natural flavonoid 7,8-DHF 
may be a better choice for a prenatal therapy.  
 
In conclusion, the current study shows that prenatal treatment with 7,8-DHF has a positive influence 
on prenatal neurogenesis and cortical cellularity in a mouse model of DS. Since 7,8-DHF is orally 
bioavailable, a food supplementation with this flavonoid during pregnancy and in the early postnatal 
period may be considered as a safe preventive therapy for an overall improvement of brain 
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